GENEGO IS AWARDED NCI GRANT FOR DEVELOPMENT OF SYSTEMS BIOLOGY DATABASE AND TOOLS FOR NUTRITION IN CANCER IN COLLABORATION WITH THE FDA

St Joseph, Michigan, September 30th, 2008 - GeneGo Inc., a leading provider of databases, tools and services in systems biology, announced today that they were awarded with a Phase I SBIR grant from the National Cancer Institute (NCI) for the development of a platform for understanding the influence of nutrients on cancerogenesis and cancer prevention. GeneGo will collaborate with FDA investigator, Jim Kaput Director of Personalized Nutrition and Medicine, on the project. The new platform will include a comprehensive manually curated database on nutrition, an OMICs data repository, advanced search and statistical modeling tools.

“For the last 60 years, it has been well established that cancer and nutrition are intrinsically connected,” said Yuri Nikolsky, CEO of GeneGo and the grant’s PI. “However, this knowledge is scattered in thousands of sources, which are difficult to annotate and categorize. We will assemble the first specialized database on the topic and develop automated tools for data analysis. The new platform will be primarily targeting healthcare professionals and nutritionists.”

Download this press release in PDF format.

MD ANDERSON BECOMES A GENEGO CENTER OF EXCELLENCE USING METACORE FOR ONCOLOGY RESEARCH

St. Joseph, MI. September 2nd, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that MD Anderson has become a certified GeneGo Center of Excellence. MD Anderson researchers will have institution-wide access to GeneGo’s MetaCore data analysis suite, training and advanced support. MD Anderson specializes in cancer treatment and research and is well known for its advanced clinical trials programs. MetaCore will be used throughout many research programs both as a central data repository, management and collaboration platform for clinical OMICs data and as an integrative pathway analysis suite.

Mary E. Edgerton, a pathologist performing cancer research at MD Anderson and a long-term client, says “I have been using Metacore for many years in my research into pathways and networks that control aggressive behavior in cancers. I am currently using it to infer networks from analysis of gene expression array data for pathways in lung, brain, and breast cancer. I also use the curated pathways to formulate mathematical models of molecular networks that predict tumor behavior using multiscale modeling. Not only do I find the product to be very useful, but I also appreciate the responsiveness of the staff at Genego to my technical questions and suggestions.”

“MD Anderson is renowned for their pioneering work in oncology, I have known some of the MD’s there for a while and I admire their dedication to their patients and to working hard to find cures.” said Julie Bryant, GeneGo’s VP of Business development. “We are proud to have them as an institution customer and a Center of Excellence. We have a large development program in the area of cancer system biology tools supported by NCI and we are glad to see this work appreciated by some of the best oncology professionals in the world working at MD Anderson.”

Download this press release in PDF format.

UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE BECOMES A GENEGO CENTER OF EXCELLENCE

St. Joseph, Michigan, July 15th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that the University of Miami Miller School of Medicine has become a certified GeneGo Center of Excellence (COE). Miller School of Medicine researchers will have access to GeneGo’s MetaCore, training and advanced support. COE will provide a pathway analysis environment and support for all the school’s researchers. They will also act as a training facility for GeneGo in the University of Miami.

“We are looking forward to working with GeneGo as the company provides the kind of forward-looking bioinformatics software that we are excited to use,” said Sawsan Khuri, Ph.D., assistant research professor at the Center for Computational Science at the University of Miami Miller School of Medicine. “The technology will be extremely useful for researchers here, especially those at the Miami Project to Cure Paralysis and the Miami Institute for Human Genomics, both of which will benefit greatly from the collaboration with GeneGo as we work toward new scientific breakthroughs.”

“The University of Miami has some important thought leaders in this field and we are pleased to be working with them” said Julie Bryant, Vice President of Business Development at GeneGo. “The school of medicine works with one million patients annually and it is encouraging that we can help them to improve their quality of life.”

Download this press release in PDF format.

YALE KECK MICROARRAY CENTER BECOMES A GENEGO CENTER OF EXCELLENCE

St. Joseph, MI. July 8th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that Keck Microarray Center at Yale has become a certified GeneGo Center of Excellence (COE). Yale researchers will have access to GeneGo’s MetaCore, training and advanced support.

The W. M. Keck Foundation Biotechnology Resource Laboratory (Keck Lab), one of the largest biotechnology laboratories of its kind in academia, is a world leader in the field of genomics and proteomics. The Keck Microarray Resource is also a part of the NIH-Neuroscience supported Yale Microarray Center for Research on the Nervous system. The Yale Microarray Center is one of four national centers which together form a Consortium that provide gene expression and genotyping services at significantly reduced costs to approximately 10,000 NIH-funded neuroscientists from 15 branches of NIH that are part of the NIH-Neuroscience Blueprint.

It is anticipated that MetaCore will be used at Yale to study basic and translational research; cancer biology; neuroscience research; and other clinical conditions. Overall the COE will provide a pathway analysis environment and support for all the University’s researchers and will also act as a training facility for GeneGo.

“MetaCore is being heavily used by our users and we find it to be very intuitive, easy to use and powerful tool for performing pathway analysis of the microarray data,“ said Dr Shrikant Mane, Director of Keck Microarray Resource.

“Neurosciences is one of the key diseases we have chosen to focus on this year and working with Yale is important to GeneGo as they are a leader in this field,” said Julie Bryant, GeneGo’s VP of Business development. “We are very pleased to have them as a GeneGo Center of Excellence.”

Download this press release in PDF format.

VTT TECHNICAL RESEARCH CENTRE OF FINLAND LICENSES METACORE FROM GENEGO FOR CANCER RESEARCH AND DIAGNOSTICS

St. Joseph, MI. June 24th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that VTT has licensed MetaCore^TM. VTT develops novel high-throughput methods for cancer research, drug discovery and diagnostics. The focus is in investigating mechanisms of cancer development and progression, identification of therapeutic targets and exploration of the mechanism of action of anti-cancer compounds. VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects to identify pathways and networks important in translational cancer research.

There are 85 researchers and staff members working in VTT’s Medical Biotechnology Knowledge Centre in Turku. The research is funded by the European Commission and the Academy of Finland. VTT accommodates two EU Marie Curie Centre of Excellence teams and coordinates the Academy of Finland Centre of Excellence for translational genome-wide biology. Further information on VTT: http://www.vtt.fi.

“VTT was our first customer in Finland and an important internationally recognized cancer research center,” said Julie Bryant, GeneGo’s VP of Business development. “We have seen a growing need for analysis platforms focused in disease areas recently. We responded by developing disease pathway ontologies, biomarker and drug databases and new interactome analysis tools. We are pleased that our expertise in cancer is appreciated by professional molecular oncologists at VTT.”

Download this press release in PDF format.

GENEGO IS AWARDED NCI GRANT FOR DEVELOPMENT OF SYSTEMS BIOLOGY PLATFORM FOR INTEGRATIVE DATA ANALYSIS IN CANCER

St Joseph, Michigan, June 17th, 2008 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today that they were awarded a Phase I SBIR from National Cancer Institute (NCI) for the development of a platform for functional data analysis in cancer. GeneGo will collaborate with investigators at Dana- Farber Cancer Institute, Boston on the project. The system, MetaMiner (Oncology) will combine pathway and network analysis tools, act as a OMICs data repository and have advanced statistical tools based on functional descriptors.

“MetaMiner (Oncology) is a new generation pathway analysis tool, specifically tailored for biologists, clinicians and chemists working in different cancer areas,” said Yuri Nikolsky, CEO of GeneGo and the grant’s PI. “Neoplasms are tremendously complex diseases, with many hundreds of perturbed pathways, both in terms of gain and loss of functions. We need to understand in a database structure the causal relationships between the involved pathways and the dynamics of pathway activation during tumorigenesis. These are two main goals of the MetaMiner project.”

“There are many “generic” pathway tools on the market, helpful to some extent in cancer data analysis. However, none of them is centered around cancer biology, which is essential,” said Kornelia Polyak, an Associate Professor at Dana-Farber Cancer Institute and a consultant on the grant. “Another focus will be on the development of pathwaybased tools for integration of different types of OMICs data – somatic mutations, high copy number genes, epigenetics, gene expression, proteomics and metabolomics.”

Download this press release in PDF format.

KINEMED LICENSES GENEGO'S METACORE

St. Joseph, Michigan, June 10th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that KineMed Inc. has licensed MetaCore for application to its ongoing multi-center Phase II prognostic study of chronic lymphocytic leukemia (CLL). KineMed’s kinetic biomarker of CLL flux as a predictor of disease course is intended to stratify indolent (simmering) versus aggressive disease.

“KineMed’s biological pathway insights and GeneGo’s database for systems biology link network complexity to physiologic phenotypes and disease genotypes which is one of the primary goals for personalized medicine. These insights will answer the challenge of determining the right medicine for the right patient at the right time”, said Gregory Hayes, Ph.D., Director of Oncology Research at KineMed. GeneGo’s genetic pathway database aligns with KineMed’s phenotypic pathway analysis and facilitates identification of genetic polymorphisms and expression patterns that directly link genetics with KineMed’s in vivo disease biomarker.

“Building cancer specific pathway analysis software and databases is a key focus area for GeneGo this year, ” said Julie Bryant, VP business development. " We have a lot of expertise in this area that is reflected in our grants and publications in Science and Cancer cell".

Download this press release in PDF format.

GENEGO EXTENDS AGREEMENT WITH MERCK & CO., INC.

St. Joseph, Michigan, June 3rd, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck & Co., Inc. has extended its global enterprise agreement. This agreement provides Merck with access to GeneGo’s content through MetaBase which includes access to MetaCore and MetaDrug content and GeneGo’s internal database of disease biomarkers.

“Effective use of powerful systems biology data mining & analysis solutions have become an essential component of modern day drug discovery and development,” said Julie Bryant, VP business development. "Merck is one of our first customers and we are pleased that they have chosen to renew and extend their agreement."

Download this press release in PDF format.

GENEGO’S FIRST CUSTOMER IN HONG KONG; THE CHINESE UNIVERSITY OF HONG KONG

St. Joseph, Michigan, April 22nd, 2008 – GeneGo, Inc., the leading provider of software and databases for systems biology and pathway analysis, today announced that the Chinese University of Hong Kong, Pediatric department will be using GeneGo’s MetaCore™. Broad coverage of biomarkers and drug targets for a large variety of diseases in MetaCore was an important factor for the decision to license MetaCore, as well as species-specific content for the main animal models used in disease research.

“We are very pleased to have the Chinese University of Hong Kong as a customer as we extend our reach in Asia,” said Julie Bryant, VP business development. “Hong Kong is a very sophisticated market with top notch researchers in oncology and other key diseases, and we are glad that the CUHK group has chosen MetaCore. Disease area specific content is one of our important development goals for the next 3 years.”

Download this press release in PDF format.

THE SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE JOINS THE METAMINER CARDIAC CONSORTIUM

St. Joseph, MI. April 15th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that The Scripps Translational Science Institute have joined the MetaMiner Cardiac Consortium. The goal of the Consortium is to build the first systems biology and pathway analysis platform for cardiovascular diseases in the world. The Consortium members will vote on deliverables that will include disease specific pathway maps and networks built by experts in the field. GeneGo will also develop relevant ontologies for cardiovascular diseases and drugs. The MetaMiner environment will also serve as a repository for OMICs and other experimental data.

“We are very excited to have The Scripps Translational Science Institute, lead by Dr. Eric Topol, Director as a member. He is a world renowned expert in this field and will provide strong leadership for the project,” said Julie Bryant, GeneGo’s VP of Business development. “The cardiovascular disease area is complex and a challenging field. We believe that MetaMiner Cardiac will have an impact on both basic research and drug discovery in this area.”

Download this press release in PDF format.

GENEGO ROLLS OUT METAMINER CYSTIC FIBROSIS -- THE FIRST DISEASE - SPECIFIC SOFTWARE PLATFORM TO ADVANCE DRUG DISCOVERY

St. Joseph, MI. March 26th, 2008. GeneGo, Inc., the leading systems biology tools company, announced today the release of MetaMiner Cystic Fibrosis, a first of its kind software and database platform designed to help advance drug discovery for cystic fibrosis, a lifethreatening genetic disease. This novel, disease-specific tool will provide the cystic fibrosis research community with state-of-the art methods for integrating and analyzing cystic fibrosis data.

Cystic Fibrosis Foundation Therapeutics, Inc., a non-profit affiliate of the Cystic Fibrosis Foundation, provided funding and guidance to the project with the goal of leveraging systems biology technology and accumulating data in order to accelerate drug discovery for this disease. Cystic fibrosis affects 30,000 people in the United States, and ten million Americans are symptomless carriers of a CF gene.

“MetaMiner Cystic Fibrosis is an important new tool for the cystic fibrosis research community,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “It will allow the integration of important new results with existing literature and speed up the rate of insights that can lead to new therapeutic interventions.”

“We are very pleased to announce the completion of the initial phase of the project,” said Julie Bryant, GeneGo’s VP of Business Development. “We enjoyed working with the Foundation and the team of world-class experts they assembled for this project. In phase one, we built a database of all relevant small experiments information on the disease as well as over 30 cystic fibrosis specific pathway maps and networks. We believe this environment will help find a cure for cystic fibrosis faster as we move in to the next phase of the collaboration”.

MetaMiner Cystic Fibrosis includes off-the-shelf GeneGo products -- MetaCore, MetaDrug and MapEditor -- as well as cystic fibrosis experiments content annotated by GeneGo in the form of disease maps, networks and a database of biomarkers and active compounds. A committee of researchers from the cystic fibrosis community guided the cystic fibrosis-specific annotation under the sponsorship of CFFT. MetaMiner Cystic Fibrosis provides researchers with the ability to interpret emerging data from global experiments, like arrays or proteomics, and link it with published literature on cystic fibrosis.

GeneGo’s MetaMiner Cystic Fibrosis will enable cystic fibrosis researchers to visualize complex information and prioritize research initiatives. It will also help researchers to be open to other interpretations of their experimental data and allow them to rank the significance of their results. Additionally, MetaMiner Cystic Fibrosis will reduce the learning curve for researchers moving into the CF field and permit new investigators to understand outcomes more quickly.

Download this press release in PDF format.

GLAXOSMITHKLINE EXTENDS GENEGO LICENSE AND ADDS NEW PRODUCTS

St. Joseph, MI. February 5th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that GlaxoSmithKline has extended their licensing agreement with GeneGo and have added additional capability. This will provide GlaxoSmithKline researchers with global access to MetaCore, MapEditor and MetaBase. MetaCore is GeneGo’s flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases. MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GlaxoSmithKline will also use the platform as a repository of all types of experimental data as well as resulting analyses. All of this information can be easily shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating intereractive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

“We have a good working relationship with GlaxoSmithKline developing new products such as our pay as you go 1-2-3 Workflow,” said Julie Bryant, GeneGo’s VP of Business development. “We will continue to work closely developing new functionality, tools and content for GlaxoSmithKline.”

Download this press release in PDF format.

U.S. ARMY CENTER FOR ENVIRONMENTAL HEALTH RESEARCH LICENSES METACORE FOR BIOMARKER RESEARCH

St. Joseph, Michigan, January 29th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the U.S. Army has extended their license of MetaCore. The US Army Center for Environmental Health Research will use MetaCore in its Biomarker Discovery Program to identify novel biomarkers for exposure to TICs/TIMs in order to provide enhanced health surveillance for military personnel.

“We are pleased that institutes on the bleeding edge of technology such as the U.S. Army are using MetaCore in their research” said Julie Bryant, Vice President of Business Development at GeneGo. “Soldiers and other service members can be exposed to a large number of toxic industrial chemicals and materials (TICs/TIMs) from occupational sources, from environmental pollution or as result of military activity. We are proud that our software may help in an ongoing research on environmental pollution dangers”.

Download this press release in PDF format.

FINNISH RED CROSS LICENSES GENEGO PRODUCTS

St. Joseph, MI. January 22nd, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that the Finnish Red Cross Blood Service has licensed GeneGo’s bioinformatics and chemoinformatics suites MetaCore™ and MetaDrug™, respectively, to be used in a variety of research and clinical projects.

“The entrepreneur knowledgebase behind the merged platform is impressive in the areas of cell adhesion and immunology, which is essential in blood transfusion field,” said docent Jukka Partanen, research director at the FRC Blood Service R&D.

In a joint effort with the Finnish hospitals, FRC Blood Service is collecting clinical information from nearly 70% of the patients receiving blood transfusions in the country, to optimize the blood component usage far beyond 2000 annual diagnoses. Beside the blood group and cell type analysis in disease and pregnancy, we are working with tissue typing of donors and recipients in organ, bone marrow and cord blood and bone marrow stem cell replacement transplantations.

“In the market, we have not found any other manually curated platform where multiple parallel omics data could be submitted in a batch mode in such a systems medicine fashion. We are delighted that the curation does not ignore the non-English journals and reviews patent literature as well. The principle of taking only causality and not mere association into account is critical in the era of NLP text mining servers and HTS data flood,” said Jukka Partanen.

“We are very pleased to be working with such a prestigious organization,” said Julie Bryant VP of Business development for GeneGo. “Disease-centric systems medicine is a natural and logical step in the development of our tools and databases and we are excited to see healthcare organizations such as Finnish Red Cross using it in such practical and important way.”

Download this press release in PDF format.

GENEGO COLLABORATES WITH UNIVERSITY OF ILLINOIS AT URBANACHAMPAIGN TO INCLUDE BOVINE SPECIES INTO METACORE

St. Joseph, Michigan, January 15th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced they will include bovine orthologs in the next release of MetaCore, in collaboration with University of Illinois Urbana-Champaign whom identified the matching bovine-mouse-rat-human orthologous pairs. The latest version MetaCore 4.5 already includes mouse, rat, fly, worm, yeast, chicken, chimpanzee, Rhesus Macaque, dog, and Malaria plasmodium, making MetaCore the broadest platform available for non-human species research. MetaCore also has a unique rat and mouse specific interaction database called MetaRodent.

“We are happy to collaborate with UIUC on inclusion of bovine orthologs into MetaCore. They did a superb job of ortholog identification”, said Tatiana Nikolskaya, President of GeneGo. “With the rapid advance of sequencing technology, new eukaryotic genomes are becoming available at an increasing rate, and each genome comes with an academic research community. And as each community requests tools for functional analysis of their organism of choice, we see an increasing demand for expansion of the list of species in the database.”

“GeneGo is definitely leading the way for species coverage,” said Julie Bryant, VP of Business Development. “We provide more species and unique interaction databases for mouse and rat that will grow as we continue to innovate.”

Harris Lewin, Principal Investigator and Director of the Institute for Genomic Biology at UIUC had this to say”We were very pleased to work with the team at GeneGo on the identification of cattle orthologs. My group feels that MetaCore is currently the premier product for data mining and pathway analysis. The addition of bovine orthologs of human, mouse and rat genes to MetaCore will make the recently sequenced cattle genome more accessible for functional genomics and systems biology.”

Download this press release in PDF format.

UC BERKELEY EXPANDS MOLECULAR TOXICOLOGY CURRICULUM TO INCLUDE GENEGO'S PLATFORM

St. Joseph, MI. January 8th 20th, 2008 – GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that UC Berkeley will expand the use of its MetaCore/MetaDrug Discovery Platform in their Computational Toxicology course, a required component for Molecular Toxicology majors, and in undergrad honors research programs. The agreement will provide students with chemical structure, network and pathway analysis tools needed to analyze complex omics datasets and to predict and understand the beneficial and potentially harmful effects of chemicals in humans and other species.

“When we designed our Computational Toxicology course a few years ago we anticipated a shift in the future toward ‘systems biology’ that is, looking at the complex interactions of metabolic, genetic, protein, and cellular elements with the goal of modeling entire systems in relation to chemical stresses,” said Dale Johnson, Pharm.D., Ph.D., Adjunct Professor, who designed and teaches the Computational Toxicology course. “The complexity of these chemical/biological interactions resulting from environmental exposures, food sources, or pharmaceutical compounds, highlights our thinking that an overall systems approach will be necessary if relevant advances are to be made in applying computational solutions. GeneGo has presented us with an outstanding platform that continues to grow in functionality each year. We are extremely pleased to be able to utilize MetaCore/MetaDrug as the core part of our coursework.”

“We are pleased with the decision of UC Berkeley's Department of Nutritional Sciences and Toxicology to include our tools in its curriculum, which is one of the very best in the world,” said Julie Bryant, Vice President of Business Development for GeneGo. “The study of fundamental biology is changing quickly with omics technology and systems level analysis, and these changes affect application fields such as toxicology. UC Berkeley will be educating a new breed of toxicology researchers that are needed for the future success of taking drugs to market.”

“Today’s drug and chemical safety assessment process increasingly leverages information from many different sources,” said Dr. Richard Brennan, GeneGo’s Director of Toxicology. “Molecular toxicologists need to be able to put traditional toxicology measurements in the context of chemical information as well as biochemical, gene expression, protein and metabolite data. Industry needs scientists well-versed in complex systems biology data, and in the powerful and flexible analysis tools increasingly used in safety assessment. UC Berkeley is leading the way in providing training in current and emerging technologies, and we are pleased to be able to contribute to this cutting-edge program.”

Download this press release in PDF format.

GENEGO INTEGRATES WITH CYTOSCAPE

St. Joseph, MI. December 18th, 2007 – GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that its platforms for functional data analysis, MetaCore and MetaDrug, are now integrated with Cytoscape. MetaCore users will now be able to use Cytoscape network visualization tools and have access to dozens of its open source and commercial plug-ins. The integrated solution was presented at the Cytsocape annual meeting in Amsterdam, November 6-9.

Originally developed at the Institute for Systems Biology, Cytoscape is a bioinformatics software platform for visualizing molecular interaction networks and integrating these interactions with gene expression profiles and other state data. Additional features are available as plugins. Plugins are available for network and molecular profiling analyses, new layouts, additional file format support and connection with databases. Plugins may be developed using the Cytoscape open Java software architecture by anyone and plugin community development is encouraged.

“This was an obvious progression from our relationship with the Institute of Systems Biology,” said Julie Bryant, Vice President of Business Development for GeneGo. “The Cytoscape project has grown into, probably, the most advanced and well known developer’s community in systems biology, and we are very glad to participate in it. We know that our tools and content will be of interest for Cytoscape users.”

Download this press release in PDF format.

TNO EXTENDS LICENSING AGREEMENT WITH GENEGO AGAIN

St. Joseph, MI. December 4th, 2007 – GeneGo, Inc., the leading systems biology tools company, announced today that TNO, The European Nutrigenomics Organisation (NUGO) Consortium and The Netherlands Nutrigenomics Consortium (NGC) have extended their agreement with Genego. Further, the recently established Netherlands Toxicogenomics Centre (NTC) will soon acquire MetaCore and MetaDrug for applications in toxicogenomics.

This provides over 20 universities in Europe with access to MetaCore. GeneGo has a unique Rodent version of MetaCore with rat and mouse genes, protein complexes and interactions. This is the first species specific database which is not derived from ortholog matching. This level of detail is crucial for nutritionists and toxicologists who deduce human efficacy and toxicity based on animal models data.

‘TNO is routinely applying omics technologies to better understand the activities of nutrients and toxicants. A strong focus is on statistically and biologically driven bioinformatics towards drawing of relevant biological conclusions. We are coordinating the bioinformatics for the consortia mentioned above. MetaCore is a valuable add on to this portfolio and allows us to better understand omics data in the context of mechanisms of action. Within NuGO and NGC, Metacore is used by researchers in the fields of nutritional systems biology. Within NTC, it is used in the context of a variety of toxicological problems. Through interaction with these scientists, TNO is capable of further strengthen its scientific systems biology backbone in these areas.” said Dr Rob Stierum’ Head Toxicogenomics.

“We have established a close relationship with TNO over the years”, said Julie Bryant, GeneGo’s VP of Business development. “The projects we collaborate on include a study on cholesterol diet and drug effects on atherosclerosis and nutrigenomics. TNO is also using GeneGo products as part of their tox service offerings. We look forward to further collaborations and more publications.”

Download this press release in PDF format.

ELAN PHARMACEUTICALS JOINS GENEGO'S METATOX CONSORTIUM

St. Joseph, MI. November 27th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Elan Pharmaceuticals has joined the MetaTox Consortium. The Consortium, led by Dr. Richard Brennan, will be focused on developing systems biology tools for safety assessment of small molecule compounds and biological therapeutics. This effort will include expanding the existing tools in the MetaDiscovery™ platform with toxicity ontologies, developing “knowledge-based” predictive models (functional descriptors), manual reconstruction of toxicity pathways in human and relevant preclinical model species, and the development of simplified workflows for analyzing and reporting systems toxicology data. These tools, unique to the marketplace, will enable the members to leverage their diverse molecular toxicology data in an integrated “systems’ perspective that has not been available until now.

“The MetaTox Consortium is a cost effective vehicle for the members to develop software and expand content in systems toxicology,” said Julie Bryant, Vice President of Business Development for GeneGo. “The Consortium will propose the deliverables, to be voted on and prioritized by the members, and GeneGo will then develop and deliver the agreed-upon content and software with members’ input. All the members joining to date have said that they could not perform this amount of work internally for the membership fee, which helped to justify the business model.”

“Despite the increasing deployment of new technologies probing the molecular basis of chemical toxicity, too many investigational drugs still fail in clinical trials due to human toxicity unseen in pre-clinical safety assessment”, said Dr. Richard Brennan, Director of Toxicology at GeneGo, “The Consortium, which includes representatives from industry and from FDA, believes that part of the problem lies in a lack of appropriate data analysis tools to properly integrate the multiple data types generated by data-rich ‘omics technologies, and to convert findings from cell-based and animal models into meaningful human risk-assessments. We will focus on developing novel predictive models, while expanding our knowledge-base of toxicity information, and developing new software for ‘omics data analysis in a systems biology perspective. Alongside GeneGo’s expertise in identifying and mapping differences in human and model-species biology, these tools will facilitate a better assessment of the potential for human toxicity from preclinical tests, increasing the quality of, and confidence in, new compounds going into clinical trials. They will also contribute to understanding the causes of failure for compounds that drop out of trials, or are withdrawn from the market, for safety reasons, allowing these liabilities to be screened out of follow-up molecules.”

Download this press release in PDF format.

UTRECHT UNIVERSITY LICENSES METADRUG™ FROM GENEGO FOR DRUG INNOVATION

St. Joseph, MI. November 20th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Utrecht University will be using MetaDrug™ in their prestige master program for drug innovation. MetaDrug™ is designed for predicting biological effects such as indications, toxicity and off-target effects for new compounds structures. Its content includes xenobiotics with known activity, endogenous metabolites and reactions, as well as pathways, networks and diseases which are important for knowledge-based drug discovery. Our integration to Elsevier MDL’s Discovery Gate also helps find more information about the compounds of interest in patent databases and clinical trial databases.

“Our research students of drug innovation should learn to see the big picture as soon as possible, in order to become effective drug researchers. MetaDrug™ is state-of-the-art, but still very accessible to the novice user,” said Dr Ed Moret. “We really like the support and training they have offered to our students.”

“GeneGo is very serious about including MetaDrug™ in academic environments especially for teaching,” said Julie Bryant, Vice President of Business Development for GeneGo. “Academia pushes the limits of MetaDrug™ which allows us to further adapt it for new areas of medicinal chemistry and they publish new applications that we may not even have thought of using it in such a way.”

Download this press release in PDF format.

ELAN PHARMACEUTICALS, INC. LICENSES SOFTWARE AND DATABASES FROM GENEGO

St. Joseph, MI. October 30th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Elan Pharmaceuticals, Inc. licensed its flagship data analysis suite MetaCore™. The platform will be available to all scientists in research. MetaCore™ is designed for functional analysis of biological and chemistry data. Elan will use MetaCore™ in their neurology and autoimmune programs.

“We are very pleased that Elan chose GeneGo and we have had good interactions so far,” said Julie Bryant, GeneGo’s VP of Business development. “MetaCore™ has substantial knowledge content coverage in the areas of CNS and autoimmune diseases, which the Elan scientists can leverage in their innovative research.”

Download this press release in PDF format.

GENEGO LICENSES METACORE™ DATA ANALYSIS SUITE TO AVEO PHARMACEUTICALS

St. Joseph, Michigan, October 23rd, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that they have licensed their MetaCore™ Data Mining Suite to AVEO Pharmaceuticals. The latest version, MetaCore 4.5™, includes novel GeneGo disease enrichment and functional ontology. MetaCore™ has an in depth knowledge base for human diseases and the unique ability to concurrently visualize gene expression, proteomics, genetic and metabolic data. The suite’s data management system is designed for automated upload and handling of hundreds to thousands of genome-wide files, which makes MetaCore™ a robust OMICs repository platform of choice. MetaCore™ is used in both research and clinical groups in drug development.

“We are pleased that AVEO chose the MetaCore™ suite of products to enhance its analytical capabilities,” says Julie Bryant, Vice President of GeneGo. “AVEO’s vision and focus in cancer drug research and development is inspiring and we believe our MetaCore™ suite of data mining tools will be an asset to their efforts.”

Download this press release in PDF format.

ORGANON EXTENDS METACORE™ LICENSE AND ADDS METALINK™

St. Joseph, MI. October 2nd, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Organon, the human health care business unit of Akzo Nobel, have extended their GeneGo software and database licenses. In addition to extending their MetaCore™ license, Organon has also added MetaLink™ so that they can upload their own interaction data and visualize it in the context of MetaCore’s manually curated content.

GeneGo offers easy to use automated workflows that casual users can use and these are now also available through their new product 1-2-3 workflow™ which is a “pay as you go” business model. GeneGo also covers human, mouse, rat, dog, worm, chicken, fly, chimpanzee and yeast which is very important for our customers.

“GeneGo has demonstrated the capability to develop a good pharma oriented bioinformatics tool in the past years” said Peter Groenen, project manager for pharmacogenetics at Organon. “We have now started to use their software for more advanced projects to support our translational medicine efforts”.

“Organon has been a good, loyal GeneGo customer for years and we are pleased they have extended their license,” said Julie Bryant, GeneGo’s VP of Business Development. “We have received good development feedback from Organon over the years and implemented many of their ideas in MetaCore™”.

Download this press release in PDF format.

GENEGO ENTERS MULTI-YEAR AGREEMENT WITH BRISTOL MYERS SQUIBB FOR ACCESS TO GENEGO SOFTWARE SUITE AND DATABASES

St. Joseph, MI. September 25th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Bristol-Myers Squibb (NYSE: BMY) has licensed access to all major GeneGo products. Using the licensed GeneGo technology, research and development sites within Bristol-Myers Squibb will have the ability to start with chemical compound structures and/or genomics data to address questions from both chemistry and biology domains. Bristol-Myers Squibb can also access GeneGo tools to build their own canonical pathway maps using public, GeneGo, and proprietary data and have those maps included in statistical calculations and overlays. In addition, Bristol Myers Squibb researchers can leverage GeneGo products to overlay their own internal interaction data in the context of manually curated pathways for more elucidation.

“Bristol Myers Squibb is very important to GeneGo as they have excellent scientists who we have been collaborating with,” said Julie Bryant, GeneGo’s VP of Business Development. “We plan to continue this collaborative spirit over the next few years.”

Download this press release in PDF format.

GENEGO AND THE CYSTIC FIBROSIS FOUNDATION COLLABORATE TO ADVANCE UNDERSTANDING OF CYSTIC FIBROSIS

St. Joseph, MI. September 11th, 2007 — GeneGo, Inc. and the Cystic Fibrosis Foundation announced today their collaboration to develop a software suite for the integration and analysis of cystic fibrosis data. GeneGo’s proprietary software combines analytical tools, data content and algorithms for understanding the complex interconnected pathways that are affected in common human diseases.

“We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level,” said Robert J. Beall, Ph.D., president and CEO of the Foundation. “Using computational platforms adds to our arsenal of already existing strategies.”

The new platform, called MetaMiner™ (CF), will include off-the-shelf GeneGo products such as MetaCore™, MetaDrug™, MetaLink™ and MapEditor™. Platforms such as MetaDrug™ can help to solve various problems including a drug’s mechanism of action, toxicity and off-target effects, deduced from the structure and any kind of supplementary omics data. The product is intended to be used by medicinal chemists and biologists active in pre-clinical areas of high content and high throughput screening, bioassays, hit-to-lead. MetaMiner™ (CF) will include cystic fibrosisspecific OMICs and small experiments content annotated by GeneGo, disease maps and networks.

“We are very pleased to work with Cystic Fibrosis Foundation and the academic community which is very well organized and successful in research and drug discovery for the disease. We have a clear direction and end goals that we are focused on,” said Julie Bryant, GeneGo’s vice president of business development. “This collaboration is the first in the series of diseasecentered MetaMiner™ projects which integrate our existing data analysis tools, OMICs data warehousing and disease-specific knowledge base. We have a dedicated group of Ph.D. and M.D. scientists to work on this project.”

The project will be guided by a Cystic Fibrosis Foundation committee with a goal to leverage systems biology technology and accumulated data to advance drug discovery for this disease. MetaMiner™ (CF) is expected to be available by February of 2008 to cystic fibrosis academic researchers and drug development collaborators through access licenses.

Cystic fibrosis is a genetic disease that affects about 30,000 adults and children in the United States. It causes life-threatening lung infections and serious digestive complications. More than 10 million Americans are symptomless carriers of the CF gene.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has 80 chapter and branch offices throughout the country, and supports and accredits a nationwide network of 115 CF care centers, including 94 adult programs, which provide vital treatments and other CF resources to patients and families. For more information, visit www.cff.org.

Download this press release in PDF format.

NHLBI EXTENDS GENEGO LICENSE AGAIN

St. Joseph, MI. September 4th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that National Heart Lung and Blood Institute have extended their license again. Hundreds of researchers will have access to MetaCore™ at the NHLBI for analysis of different types of “omics” data such as gene expression, proteomics, metabolomics and SNPs and MPSS. MetaCore™ is known for its comprehensive functional ontologies including cellular and molecular processes, canonical metabolic and signaling pathways, diseases and disease networks and biomakers.

The NHLBI Genomic Core supports NHLBI investigators conducting research with the ultimate goal of understanding the pathophysiology of human diseases employing high throughput technologies. As a central part of its role, the core provides computational and research tools to investigators and helps them expand their ability to conduct genomic research through new techniques mapping gene expression data to metabolic and signaling pathways. Currently investigators sift through large gene lists trying to decipher which pathways are affected. Genego’s Metacore™ data mining software would provide statistical, visual and machine learning techniques to rationalize the extensive changes in gene expression due to experimental conditions or disease processes and DNA sequence variations. It is hoped that the application of this Metacore™ analysis program would help us decipher the key molecular mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicine.

“We are pleased to have a strong, long lasting relationship with NIH as they are the best known research organization in biomedicine,” said Julie Bryant, GeneGo’s VP of Business Development. “Over the years, their valuable feedback has helped GeneGo to develop new features and products, and we look forward to expanding relationships with their labs”.

Download this press release in PDF format.

GENEGO ANNOUNCES LICENSING AGREEMENT WITH BIOGEN IDEC

St. Joseph, MI. August 28th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Biogen Idec (NASDAQ: BIIB) licensed its data analysis suite, MetaCore. Biogen Idec researchers can study their proprietary experimental data in the context of seven functional ontologies and unique merged metabolic/signaling networks. Importantly, MetaCore manually curated content now covers 12 organisms, and enables concurrent analysis of virtually any type of OMICs data including SNPs, MPSS files, microarray gene expression, proteomics, metabolomics and custom interactions.

“Biogen Idec is such a great success story and we are pleased to help them in future achievements,” said Julie Bryant, GeneGo’s VP of Business Development. “The field of mammalian systems biology tools is mature by now, and they had multiple choices. We are glad they chose MetaCore.”

Download this press release in PDF format.

GENEGO INC LICENSES METACORE™ TECHNOLOGY TO PHILIPS

St. Joseph, MI. July 31st 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Philips Research, one of the world’s largest industrial research institutes, has licensed its MetaCore™ technology. MetaCore™ is a very flexible pathway analysis platform that can be utilized with or without experimental data. It contains a lot of domain and disease knowledge that is easily accessible to general users which answers day to day questions of what is upstream or downstream of this gene or how are these metabolites linked via pathways, relevant papers to specific diseases or all papers on a compound binding with a specific ligand.

“We are very pleased with Philips’ decision to license MetaCore™” said Julie Bryant, GeneGo’s VP of Business Development. “We have seen a surge of diagnostic companies, such as Almac Diagnostics becoming GeneGo customers over the last couple of years, and Philips is the latest addition. We welcome the expansion of the scope of systems biology applications beyond drug discovery.”

Download this press release in PDF format.

THE INSTITUTE FOR SYSTEMS BIOLOGY LICENSES METACORE™ FROM GENEGO

St. Joseph, MI. July 24th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that The Institute for Systems Biology (ISB) has licensed its OMICs data analysis suite, MetaCore™ and 1-2-3 Workflow. All ISB researchers will have access to GeneGo pathway analysis and systems biology tools. MetaCore will be integrated with Cytoscape, an open source network visualization software supported by ISB. GeneGo and ISB also plan to collaborate on several research projects.

ISB is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. Founded by Leroy Hood, Alan Aderem and Ruedi Aebersold, ISB seeks to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. ISB’s systems approach integrates biology, computation and technological development, enabling scientists to analyze all elements in a biological system rather than one gene or protein at a time.

“The manually curated content available from GeneGo is exceptional and will allow us to advance our projects,” said Dr Nat Goodman, a Senior Research Scientist at ISB. “We are initiating several research projects together that will hopefully result in publications.”

“We are happy to welcome ISB as a customer and collaborator,” said Julie Bryant, GeneGo’s VP of Business Development. “ISB, led by Dr. Lee Hood, is the premium academic institution in our field, with outstanding research and vision. We are looking forward to working with them in systems biology of human diseases.”

Download this press release in PDF format.

EXPRESSION ANALYSIS ENTERS AGREEMENT WITH GENEGO TO PROVIDE FUNCTIONAL ANALYSIS SERVICES USING 1-2-3 WORKFLOW™

St. Joseph, MI. July 10th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Expression Analysis, Inc. will be providing functional analysis (pathways and networks) add-on services to their customers. Expression Analysis is the leading microarray services and solutions provider for clinical trials customers. GeneGo’s “1-2-3 Workflow™” automatically uploads and normalizes genomics data, compares multiple expression datasets to identify their common, similar and unique components, conducts enrichment analysis in multiple knowledge ontologies such as diseases, canonical pathways and functional processes and then calculates the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report which will be supplied as an option with microarray assays delivered by Expression Analysis.

“We are very pleased to be working with Expression Analysis as they offer excellent microarray services using standardized protocols for Affymetrix GeneChip® brand technology,” said Julie Bryant, GeneGo’s VP of Business Development.“1-2-3 Workflow™ is an ideal vehicle for value-add functional analysis for OMICs service organizations as it provides a very comprehensive report quickly and in an easy-to-understand Word format at a reasonable cost.”

“Expression Analysis is committed to being a full-service genomics provider,” said Steve McPhail, CEO and President of Expression Analysis, Inc. “Our standard microarray service includes statistical analyses to identify differentially expressed genes. However, some investigators request help translating the gene list into functional relationships. The GeneGo service will provide this assistance using an established software product. We see it as a natural partnership for both companies and a definite value for our clients.”

About Expression Analysis, Inc.:

Expression Analysis, Inc. (http://www.expressionanalysis.com) is the industry's leading provider of microarray-based genomic services for clinical trials. Specializing in gene expression and genotyping assays on Affymetrix GeneChip® microarrays, the company also provides complementary services using Illumina, Luminex and Applied Biosystems' TaqMan® technology.

Download this press release in PDF format.

DR. RICHARD BRENNAN JOINS GENEGO AS DIRECTOR OF TOXICOLOGY

St. Joseph, MI. July 17th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, today announced the appointment of Dr. Richard Brennan as Director of Toxicology. Dr. Brennan is a Diplomate of the American Board of Toxicology and brings extensive experience in the pharmaceutical and biotechnology industry, with particular expertise in molecular toxicology and toxicogenomics. Dr. Brennan will lead the MetaTox Consortium, a joint industry and government effort focused on development of systems biology tools for prediction of human toxicity of new compounds. Dr. Brennans previous position was Director of Molecular and Investigative Toxicology at Iconix Biosciences, where he was a member of the team that delivered ToxFX, a toxicogenomics data management and analysis solution. Before that, Dr. Brennan was an Associate Director of Pharmacology and Cell Biology at Cornerstone Pharmaceuticals (Stony Brook, NY) and as Senior Scientist at OSI Pharmaceuticals (Farmingdale, NY). Dr. Brennan holds a Ph.D. in Chemistry from the University of Warwick, UK, and conducted post-doctoral research at the University of Manchester and at the Harvard School of Public Health before joining industry.

“We welcome Richard to GeneGo team,” said Tatiana Nikolskaya, GeneGos founder and CSO. “At this point, the field of mammalian systems biology is getting diversified in specific application areas, such as common human diseases, drug safety and medicinal chemistry. Development of next generation products in these areas requires leaders with solid domain expertise, and Richard is both a Board certified expert toxicologist and a developer of systems analysis tools. The MetaTox project, partially supported by our NIEHS Phase II grant, will include toxicity ontologies, signature networks and functional descriptors models for different types of toxicity, as well as manual annotation of toxicity relevant pathways in human, rat, mouse and in vitro models.”

Download this press release in PDF format.

MONARCH LIFESCIENCES ENTERS AGREEMENT WITH GENEGO TO PROVIDE PATHWAY ANALYSIS SERVICES USING 1-2-3 WORKFLOW™

St. Joseph, MI. June 19th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Monarch LifeSciences will be offering pathway analysis add on services to their customers. Monarch is a contract research organization with expertise in protein biomarker discovery, development and validation. The 1-2-3 Workflow™ from GeneGo automatically uploads proteomics data, compares the datasets, identifies common, similar and unique components of the datasets, conducts enrichment analysis in multiple ontologies such as diseases, canonical pathways and functional processes; calculates the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report.

“We are very pleased to be working with Monarch as they offer excellent proteomics services, which is a growing OMICs field,” said Julie Bryant, GeneGo’s VP of Business Development. “Our goal in development of 1-2-3 Workflow™ was to adapt our functional data analysis technology for occasional users, which means automation and ease of use without a compromise on quality. We believe that Monarch LifeSciences’ customers will be very happy with the analysis provided.”

“Our goal is to provide our customers with reliable proteomics data that can easily integrate into their research programs,” said Lauri Caviston, Monarch LifeSciences’ VP of Business Development. “GeneGo provides an excellent tool for taking the data we generate to the next level.”

About Monarch LifeSciences:

Monarch LifeSciences provides services in protein biomarker discovery, development and validation for the pharmaceutical and biotech industries. Monarch’s biomarker discovery services include experimental design, proprietary sample preparation methods and quantification algorithms to ensure the generation of quality data. The LifeMarker™ Assay supports both pre-clinical and clinical applications of biomarkers and provides accurate high throughput analysis of proteins without the need for an antibody. For more information, please visit the company’s web site www.monarchlifesciences.com

Download this press release in PDF format.

CHENOMX AND GENEGO OFFER METABOLOMICS DATA INTEGRATION

Manchester, United Kingdom, June 11, 2007 — Chenomx, Inc., a leading provider of software and compound libraries for NMR-based metabolomics, and GeneGo, Inc., a worldwide leader in data analysis solutions for systems biology and pathway analysis, are pleased to announce a partnership to provide metabolomics data integration between their software products.

This partnership combines Chenomx’s powerful and easy-to-use metabolomics software, Chenomx NMR Suite, with GeneGo’s MetaCore and MetaDrug Discovery platform™, providing researchers with the ability to perform sophisticated pathway analysis and visualization.

“Chenomx’s partnership with GeneGo offers several significant advantages to our shared customers,” explains Jack Newton, Director of Product Development for Chenomx. “First, our customers will now be able to combine Chenomx NMR Suite’s powerful metabolite identification and quantification capabilities with GeneGo’s pathway analysis tools, thereby improving their interpretation and understanding of the underlying biology. This integration also allows our customers to integrate genomic and proteomic data sources with their Chenomx metabolomics data.”

“We initiated this partnership based on customer requests for seamless functional analysis of their NMR and mass spec metabolomics data,” said Julie Bryant VP of business development. “Metabolic data is hugely important in diagnostics and drug discovery, as any major disease fundamentally affects core biochemical pathways. Yet, MetaCore/MetaDrug is the only product in the field which enables direct parsing, pathway and network analysis of human metabolic data and its integration with genomics, proteomics and genetic data. Now, our customers will have this functionality accessed directly from Chenomx software”.

About Chenomx, Inc.

Chenomx, Inc. is a privately-held Canadian company that specializes in the development of complex mixture analysis software for broad application in life science technologies. With world-class expertise in NMR spectroscopy, pharmaceutical sciences, and computer software, Chenomx offers a broad range of software products and compound databases to support the metabolomics communities’ research efforts. Chenomx’s flagship product, Chenomx NMR Suite, provides a rich set of tools for identifying and quantifying metabolites in complex NMR Spectra. More information on Chenomx and its solutions is available at www.chenomx.com.

Download this press release in PDF format.

GENEGO LICENSES MEDCHEM DATABASE FROM GVK BIOSCIENCES

Hyderabad - India & St Joseph, MI, USA, June 2, 2007 — GVK Biosciences (GVK BIO) announced that it has licensed its Medicinal Chemistry Database (MCD) to GeneGo, a leading provider of databases, software and services in systems biology. MCD has over 800,000 small molecule inhibitors and has associated 3 million quantitative SAR information manually extracted from over 42,000 medicinal chemistry journal articles. GeneGo will integrate this data into MetaCore™ and MetaDrug™, designed for biology and chemistry aspects of drug discovery process, respectively

G V Sanjay Reddy, Chief Executive Officer, GVK BIO: “We are excited to be working with Genego, the leading pathway analysis and systems biology company in this space. GeneGo has definitely has been an innovator in this field and we are pleased to be associated with them. Their unique chemistry offering fits well with GVK BIO database collections.”.

Julie Bryant, Vice President Business Development, GeneGo commented: “We are very pleased to work with GVK BIO. GeneGo, like our end users, drug companies, have to make “build versus buy” decisions, but it is difficult to find content that fits our high quality criteria and adds value to the databases we have already assembled. This is the first time we have accepted any third party content”.

Informatics at GVK BIO

The Informatics division is responsible for analyzing data to transform chemical / biological patterns into knowledge. Informatics offers Custom Curation, Cheminformatics and Bioinformatics services to global clients. It also licenses and sells databases to Biotech and Pharma companies. GVK BIO’s clients include 15 of the top 20 Pharmaceutical companies.

About GVK BIO

GVK Biosciences is one of Indias premier Contract Research Organizations, providing an integrated platform of research services across the Pharma R&D value chain to a growing number of global Pharma and Biotech companies. The company combines science, innovation and resources to help clients address their Drug Discovery and Development challenges. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai and Gurgaon.
www.gvkbio.com

Download this press release in PDF format.

GENEGO AWARDED PHASE II TOXICOGENOMICS GRANT BY NIEHS

St. Joseph, MI. May 15th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that they have received a $750,000 Phase II SBIR grant from National Institute of Environmental Health Sciences (NIEHS) for the development of functional descriptors for gene expression response to drugs and toxins as part of their MetaTox™ product line.

“Toxicogenomics is a mature OMICs field, with a huge amount of drug response data accumulated in industry and the public domain”, said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “However, one third of compounds are still withdrawn from clinical trials due to human toxicity unseen in pre-clinical toxicogenomics profiling. We see the problem not in the approach itself, but in data interpretation techniques, heavily focused on statistics-derived gene signatures. In this grant, we propose to develop a new concept of functional descriptors and network models for toxicogenomics data analysis, and we are happy that NIEHS share this vision”.

Download this press release in PDF format.

BOEHRINGER INGELHEIM EXPANDS GENEGO LICENSES TO GLOBAL AGREEMENT

St. Joseph, MI. April 10th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Boehringer Ingelheim have expanded their licensing agreement with GeneGo which now covers global locations and multiple departments. The agreement covers a suite of software tools and databases for functional data analysis MetaCore™, which is used for biomarker discovery, target identification and validation. MetaCore™ features a unique set of tools for parsing, visualization and analysis of metabolic data and generation of merged metabolic/signaling networks starting from compounds structures. Such capability is key for toxicity studies and medicinal chemistry.

“We have been working for Boehringer Ingelheim more than a year and we are very pleased with their decision to expand their licenses. This year, we have already seen a substantial increase in the number of MetaCore™ seats within Pharmaceutical accounts, which is partly due to maturing of functional analysis technology” said Julie Bryant, GeneGo’s VP of Business Development. “We also think that the end users, wet lab scientists, see biologically relevant results using MetaCore™ that they are not getting from other tools.”

Download this press release in PDF format.

GENEGO WINS FROST & SULLIVAN AWARD FOR BIOINFORMATICS OURSOURCING AND COMPETITIVE STRATEGY YIELDING SIGNIFICANT COMPETITIVE MARKET GAINS

St. Joseph, MI. March 13th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that they have been awarded a 2006 competitive strategy and bioinformatics outsourcing leadership award from Frost & Sullivan, competing with 150 other companies in Life sciences. Frost & Sullivan cited that GeneGo’s innovative competitive strategy had yielded significant market gains and their analysts expect such innovations will produce lasting, precedent setting trends. This information was gathered by interviews with the experts in the field, end users and the companies themselves. Frost & Sullivan also state that GeneGo is ahead in terms of innovativeness and product quality and has the unique ability to cover the whole spectrum of systems biology that other companies miss.

“The reason why GeneGo Inc.’s competitive approach in the Bioinformatics market has been considered successful is because this makes the company appear attractive in terms of profitability, sustained commercial viability and technical competence”, says Frost & Sullivan Analyst Sumitha Kannan. “The scientific community perceives the company as having a clear vision of its needs and a strategic focus on potential future growth areas.”

“We are honored to receive this award and understand its importance in this competitive field. This award is yet another validation of the high standards that GeneGo sets in the systems biology and pharmacology field” said Julie Bryant, GeneGo’s VP of Business development. “We would also like to acknowledge help and support from our customers and partners whose feedback is really important in our product development.”

To download the white paper please click here.

Download this press release in PDF format.

GENEGO’S METADRUG™ WON THE BEST IN SHOW NEW PRODUCT AWARD AT THE 2007 MOLECULAR MEDICINE MEETING

St. Joseph, MI. March 7th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that its systems pharmacology product MetaDrug 2.0™ won the “Best in Show” product award at the CHI’s Molecular Medicine Marketplace (MMM) conference held in San Francisco last week. MetaDrug™ was chosen a winner among six other systems biology products by conference attendee votes. MetaDrug™ helps to predict indications, off target effects and human toxicity for novel small molecules compounds using systems level chemoinformatics tools and manually annotated knowledge base of compound-target interactions, diseases, toxic categories, drug and endogenous metabolic pathways and signaling interactions. “We are very pleased with winning this award”, said Julie Bryant, GeneGo’s VP of Business development. “MMM is the most important trade show in our field and is attended by the top experts in systems biology, translational medicine and medicinal chemistry, whose opinion matters a great deal for us. This year, we took a considerable risk with MetaDrug™, our second product, as it competed with the latest versions of flagship suites launched by our competitors at MMM. We are glad this risk paid off”. “MetaDrug™ is a unique platform”, said Tatiana Nikolskaya, GeneGo’s CSO and President. “There are probably a hundred commercial and open source products for pathway and network analysis of biological data but virtually nothing for chemistry. Prediction of biological effects for small molecules is a tough problem. Structure-centered chemoinformatics tools do not help explain systems level effects like disease indications; and simple assembly of ligand-receptor interactions databases are not sufficient either. We spent almost three years developing patent-pending MetaDrug™ technology and we are very glad it is appreciated by the market. We are also grateful to NIH which supported MetaDrug™ with SBIR grants”

Download this press release in PDF format.

GENEGO LAUNCHES “PAY AS YOU GO” 1-2-3 WORKFLOW™ AT THE MOLECULAR MEDICINE TRI CONFERENCE

St. Joseph, MI. February 27th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today the release of a new product, 1-2-3 Workflow™, accessible via a “pay-as-you-go” model. This easy to use workflow provides casual users with an automated comprehensive functional analysis of multiple gene lists in just two clicks. All the processing is done in the background and the customers receive a report in a formatted Word file which can be shared with colleagues.

“We are very pleased to release this new “pay-as-you-go” product,” said Julie Bryant, GeneGo’s VP of Business Development. “We developed it based on many requests from our “Google-generation” customers who want the basic analysis done “within 30 minutes with one click”. The trick was to combine the “ease of use” functionality with high quality analysis GeneGo is known for and sophistication of algorithms necessary for analysis of genome-wide datasets accessing the highest quality content in MetaCore™”

“1-2-3 Workflow™ is not about stripping-down functions of our larger product, MetaCore™&rdqou;, says Tatiana Nikolskaya, GeneGo’s President and CSO.“You can consider it as a “condensed wisdom” of our data mining projects run in house in several disease areas and toxicity for several years. We wrapped this knowledge and “know how” up into a workflow with several knowledge ontologies for enrichment analysis, the most advanced network building algorithms we have and our experience in finding the most relevant biomarkers and targets”.

Download this press release in PDF format.

ST. JUDE CHILDREN’S RESEARCH HOSPITAL LICENSES METACORE FROM GENEGO

St. Joseph, Michigan, January 30th, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that St. Jude Children’s Research Hospital has licensed its data mining suite MetaCore. The latest version MetaCore 4.2 includes a novel GeneGo ontology of cellular process networks, which goes a step beyond GO ontology which is also available in MetaCore. It contains additional functional processes and more genes have been networked using GeneGo proprietary network algorithms. MetaCore has an in depth knowledge base for pediatric cancer and the unique ability to concurrently visualize gene expression and proteomics data. MetaCore also covers many species including human, mouse, rat, chicken, dog, worm, yeast and chimpanzee. MetaCore spans research, discovery and clinical trials.

Download this press release in PDF format.

GENEGO AND SPOTFIRE PARTNER TO DELIVER FASTER GENOMICS AND CHEMISTRY ANALYSIS

GeneGo’s MetaCore and Spotfire DecisionSite Fully Integrated to Improve Pharmaceutical Discovery Workflow

St. Joseph, Michigan, January 23rd, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology and Spotfire, the Information Insight CompanySM, today announced that the companies’ flagship products are fully integrated.

The integrated products allow users to analyze genomics data, including gene expression and proteomics, more quickly and accurately in Spotfire DecisionSite, and launch MetaCore to perform pathway and network analysis. DecisionSite users can also automatically upload chemical compounds into MetaCore and MetaDrug in order to study their biological effects, including mode of action and potential toxicity. The analyzed data can be sent back to DecisionSite, allowing the user to search for additional experiments run in house.

“The integration between DecisionSite and MetaCore and MetaDrug provides our mutual customers with a more powerful environment, improving workflow and accelerating discovery from their experimentation and content,” said Christian Marcazzo, Senior Director of Life Science Analytics for Spotfire. “This integration is a brilliant demonstration of the flexibility of the DecisionSite platform to evolve with the changing needs of our pharmaceutical industry customers.”

“We received numerous requests from our mutual customers for seamless integration with Spotfire. This integration is unique as both GeneGo’s and Spotfire’s products enable concurrent analysis and display of both biological and chemistry data” said Julie Bryant, Vice President of Business Development at GeneGo. “GeneGo has an open partnering philosophy and we always look forward for expansion of our product integration space. We are very pleased with the current project with Spotfire, the dominant player in the data analysis market.”

About Spotfire

Spotfire, the Information Insight CompanySM, is a leading provider of enterprise analytics software that helps professionals quickly discover new and actionable insights in information. For thousands of business professionals faced with day-to-day decisions, Spotfire offers a visual and interactive analytics experience that helps them make decisions with speed and confidence. Distinguished by its ease of use and analytic power, Spotfire software rapidly reveals unseen threats and illuminates new opportunities, creating significant economic value. Spotfire’s customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit www.spotfire.com.

Spotfire, DecisionSite and Spotfire DXP are trademarks or registered trademarks of Spotfire, Inc., except in the European Community where Spotfire and the products listed are trademarks of Spotfire AB. Other company or product names may be the trademarks of their respective owners.

Download this press release in PDF format.

ALMAC DIAGNOSTICS MULTI YEAR LICENSE AGREEMENT WITH GENEGO

CRAIGAVON, Northern Ireland and St. Joseph, Michigan, December 19th, 2006 – Almac Diagnostics, a division of Almac Group, and GeneGo, Inc., a leading provider of software, databases and services for systems biology, announced today that Almac Diagnostics has licensed their flagship data mining suite, MetaCore™.

The multiple-year agreement will allow Almac Diagnostics’ scientists in the UK and US to use MetaCore™ in the development of novel microarray-based products for the diagnosis and treatment of cancer. Almac Diagnostics’ Genomic Services division that delivers comprehensive genomic services to academic, biotech and pharmaceutical customers will also use MetaCore™.

Almac values the completeness and quality of content coverage in MetaCore™ from signaling ligands to core metabolic pathways, its intuitive interface and comprehensive automated analysis workflows.

“We compared several platforms before we finally decided on GeneGo. MetaCore™ has broad and deep, high quality content coverage, which was important to us. Furthermore its ability to work with mixed IDs is critical for our internal R&D work and service offerings based on our unique DSA™ (patent pending) research tools,” said Dr. Vitali Proutski, Bioinformatics Manager at Almac Diagnostics. “We were also very impressed by GeneGo’s responsiveness and strong customer support which we feel is vital in relationships with our partners.”

“We are very pleased to welcome Almac Diagnostics as a new GeneGo customer. Our experience with them during the thorough evaluation was very positive, with constant communication between Almac Diagnostics and GeneGo scientists,” said Julie Bryant, Vice President of Business Development at GeneGo. “Our products are gaining momentum in clinical diagnostics, both on the development side and among practitioners. Almac combines both as a highly reputable, scientific oriented new generation CRO.”

About Almac Diagnostics

Almac Diagnostics develops, markets and supplies, leading edge genomic products and services. It is a member of the Almac Group, an organization providing services from R&D through clinical development to manufacture of pharmaceutical product. Almac Diagnostics has two divisions:
The Genomic Services division provides all inclusive gene expression, SNP and bioinformatics services to academia, biotech and pharmaceutical companies. These services include analysis on our unique DSA™ research tools, which provide the ability to detect the maximum information in a given cancer type. Almac Diagnostics is the first Authorized Affymetrix Service Provider to successfully gain accreditation to ISO17025 for our comprehensive Gene Expression Microarray and Bioinformatics services.
The Research & Development Division develops, using proprietary DSA™ research tools, new tests that will change the way cancers are managed in the future. These proprietary arrays provide unique information for individual cancer types and represent a stable, long-term platform for the development of clinical diagnostics.
www.almacgroup.com

Download this press release in PDF format.

CHANG GUNG UNIVERSITY UPGRADES AND EXTENDS THEIR AGREEMENT WITH GENEGO TO ACCESS METACORE™ AND MAPEDITOR™

St. Joseph, Michigan, December 12th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that Chang Gung University (CGU), Taiwan has upgraded their MetaCore™ web portal license to a permanent in house server installation. CGU has also licensed MapEditor™, a new customization product for drawing and editing pathways maps using MetaCore's high quality, manually curated back end content database. An extensive group of CGU researchers will be using MetaCore™ and MapEditor™ for analysis of gene expression, proteomic and metabolomic data in a broad range of life science fields. They also plan to produce their own pathway maps using MapEditor™ that will be accessible to the Chang Gung University research community. The agreement was made possible through GeneGo's Taiwanese distributor Tri-I Biotech.

"GeneGo's MetaCore™ and MapEditor™ is one of the integrated bioinformatics platforms installed in the Chang Gung Bioinformatics Center for analysis of data generated from research projects of different disciplines. Current and ongoing projects include the identification of biomarkers that can reveal the presence of nasopharyngeal carcinoma (NPC) in a blood test; the Trichomonas vaginalis Systems Biology Project and the Acanthamoeba Expressed Sequence Tag Project. These powerful tools will highly improve our research stretch" said Professor Tang.

"We are pleased that Dr. Tang has extended his MetaCore™ license and added our latest product, MapEditor™" said JulieBryant, Vice President of Business Development at GeneGo. "Taiwan is an important, fast growing market for us, as its research is well known in different areas of life sciences."

Download this press release in PDF format.

GENEGO LAUNCHES TWO NOVEL PATHWAY EDITING PRODUCTS, MAPEDITOR™ AND METALINK™

St. Joseph, Michigan, October 24th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced the launch of two new products, MapEditor™ and MetaLink™. The products are add-on modules in the MetaCore™ environment designed for integration, editing and mapping custom interactions data.

MapEditor™ enables the generation of custom pathway maps starting from scratch, converting a network in to a pathway map or editing one of the existing 500 proprietary maps from MetaCore™. This allows GeneGo customers to develop NEW pathway maps based on their proprietary data that is only accessible to their company. GeneGo’s maps are becoming the industry standard and are currently widely available via the iPath™ Online BioAtlas from Invitrogen at www.invitrogen.com/ipath.

MetaLink™ allows users to batch upload their own protein association data produced by yeast-twohybrid screens, gene co-expression, pull-down assays, text mining and other methods in MetaCore™ and build networks on the fly overlaying their interactions in the context of manually curated interactions. The accompanying gene expression and other molecular omics data can be mapped and prioritized on the resulting customized networks.

“MapEditor™ and MetaLink™ were developed in conjunction with our pharmaceutical customers, who needed customization tools to deal with their proprietary experimental interactions data not yet reported in the literature,” said Julie Bryant, Vice President of Business Development at GeneGo. “The new products round up our customization suite of tools which also includes PathwayEditor, launched two years ago. With these additions, the MetaCore™ platform has become a truly universal environment for functional data mining, capable of handling analysis of any type of molecular omics data and gene/protein association data. The main functional blocks in MetaCore™, canonical maps and networks are now completely editable, seamlessly integrated and internally consistent.”

Download this press release in PDF format.

DOW NEUROBIOLOGY LABROATORIES EXTENDS THEIR METACORE™ LICENSES FROM GENEGO

St. Joseph, Michigan, October 17th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Robert S. Dow Neurobiology Laboratories extended their MetaCore™ license. Scientists in RSDNL have been using MetaCore™ for analysis of proteomics and gene expression data for understanding ischemic brain injury and its prevention. MetaCore™ is an expert yet easy to use platform for functional data mining. With intuitive, one-click workflows, it provides bench biologists with a comprehensive overview of pathways, networks, functional modules and processes perturbed in disease and under drug treatment.

“During the past year, we have used MetaCore™ in analyzing our quantitative proteomic data on ischemic rodent brains,” said Dr. An Zhou, a scientist at the RSDNL. “MetaCore™ allows us to efficiently handle multiple sets of high throughput proteomic data with statistics and visual presentation, as well as to identify pathways and networks that are unique to different ischemic conditions of the brain”.

“Research at the Robert S. Dow Neurobiology Labs,” said Dr. Roger Simon, the director of RSDNL, “is concerned with the anatomic, physiologic and neuropathologic aspects of brain and nervous system function, with a focused emphasis on the molecular and cellular mechanisms of neuronal injury and repair that are manifest in stroke and epilepsy. The proteomic and genomic responses to ischemia and particularly the phenomenon of ischemic tolerance and its neuroprotective mechanisms in the brain, are areas of concentrated interest”. Currently there are multiple NIH-funded studies in the RSDNL that address proteomic and genomic changes in the brain after ischemia. The other areas of research interest in the RSDNL include epileptic and traumatic brain injury.”

“We are pleased to see more researchers using proteomics data as well as expression data in design of their experiments” said Julie Bryant, Vice President of Business Development at GeneGo. “Comparing multiple data types is essential; equally important is to depict pathways and networks for biologically meaningful data integration.”

Download this press release in PDF format.

GENEGO INC. IS AWARDED PHASE II NCI GRANT FOR NETWORK BIOMARKERS IN BREAST CANCER

St. Joseph, Michigan, October 3rd, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, announced today that they have been awarded a Phase II SBIR grant from the National Cancer Institute for discovery of new biomarkers implicated in breast cancer based on network analysis. The research program includes a novel large scale gene expression and genotyping study to be run at Mayo Clinic and data analysis in MetaCore™, GeneGo’s flagship data mining platform.

“We are very happy to receive this Phase II award from NCI in the current highly competitive environment as it validates our commitment to scientific research and our novel, innovative ideas in pathway analysis”, said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “In Phase I, we made some exciting new findings in sub-categorization of breast cancers based on network analysis of previously published microarray expression data. However, the biomarkers found in such “metaanalysis” have to be validated in a new design study in a stringent clinical environment. We are pleased to collaborate with Mayo Clinic, a world leading institution in clinical and research oncology. The microarray and genotyping assays will be conducted at Mayo labs, and the analysis will be performed with state-of-the art translational medicine and systems biology tools”.

Download this press release in PDF format.

MERCK KGAA EXPANDS AND EXTENDS THEIR LICENSE OF METACORE™ FROM GENEGO

St. Joseph, Michigan, September 26th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck KGaA, Germany, (in the U.S.: EMD) has expanded their MetaCore™ license to allow all Merck KGaA employees to access MetaCore™ and the license is in perpetuity. Merck KGaA values the completeness of content coverage in MetaCore™ from signaling ligands to core metabolic changes, its intuitive interface and the system’s applicability in many therapeutic areas and biomarkers.

“We see MetaCore™ as a further step into systems biology, a novel discipline which holds much promise for pharmaceutical research,” said Dr Friedrich Rippmann, Director of Bio- and Chemoinformatics.

“We are very pleased to expand our relationship with Merck KGaA. Our experience with them as a customer is very positive, with excellent, constructive, feedback and open exchange of development ideas” said Julie Bryant, Vice President of Business Development at GeneGo. “Now, more groups at Merck KGaA will be able to use MetaCore™ in both early discovery and new compound safety testing.”

Download this press release in PDF format.

WASHINGTON STATE UNIVERSITY EXTENDS METACORE™ LICENSES FROM GENEGO

St. Joseph, Michigan, September 19th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Washington State University Tri-cities has extended their license of MetaCore™. MetaCore™’s new release 4.0 has unique features that give researchers a multi-level analysis of experimental data with respect to functional processes, diseases and consensus pathways in just one click.

“We have been loyal MetaCore™ users for quite some time now and we have been able to make significant progress in our projects supported by the Department of Energy’s Low Dose Radiation Research Program. The software helped us to interpret proteomic data from irradiated cells and to identify pathways responsible for cytokine release following radiation exposure. Understanding these pathways is important for both radiation protection standards and effective use of radiation therapy to treat cancer,” said Dr. John Miller, Associate Professor, Washington State University Tri-Cities, and Emeritus staff member at Pacific Northwest National Labs. “We like the openness of MetaCore™ that allows us to understand our data in terms of biological processes, not just lists of identified proteins.” Dr. Miller focuses on biological and environmental research including radiation induced protein release.

“We are very pleased that an exemplary academic such as Professor Miller finds high value in MetaCore™ as a research tool” said Julie Bryant, Vice President of Business Development at GeneGo. “Academic scientists are a fast growing and invaluable customer base for GeneGo. We like working with academics because of the high quality of research and challenging yet constructive feedback. GeneGo is known as the innovator in functional analysis, and many of our development ideas come from academic collaborations and requests.”

Download this press release in PDF format.

NIDDK RENEWS METACORE™ LICENSE AND COLLABORATES WITH GENEGO IN DIABETES RESEARCH

St. Joseph, Michigan, August 15th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH), has renewed its MetaCore™ license from GeneGo to continue a research collaboration with GeneGo on functional analysis of insulin-resistant diabetes in human and animal models. Diabetes, obesity, and other metabolic disorders are priority areas in GeneGo’s effort on annotation of pathways and biological networks involved in common human disorders.

“Diabetes and metabolic diseases in general are of great importance for our pharmaceutical and academic customers, and we do our best to stay on top of current science in this area” says Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “Our collaboration with NIDDK, a leading research institution in metabolic diseases, is a very important part of our development program in this field.”

Download this press release in PDF format.

GENEGO IS AWARDED PHASE II SBIR GRANT FOR SYSTEMS PROTEOMICS PLATFORM

St. Joseph, Michigan, August 8th, 2006 – GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today that they have received a $750,000 Phase II SBIR grant from the Department of Defense for the development of a systems biology suite for functional analysis of proteomics data. In Phase II, GeneGo will adapt its data-mining platform, MetaCore™ for handling different types of proteomics data and implement new algorithms for reconstruction of protein-state specific biological networks and pathways.

“Proteomics is a central component of OMICs technologies, as it is the active protein complexes and pathways which carry out most cellular processes,” said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “However, proteomics datasets are substantially different from simpler microarray gene expression or DNA sequence data. Each protein has to be considered as a set of condition-specific posttranslational modified isoforms and splice variants, each with its own interactions space. In most cases, “small experiment” data is not available for isoform interactions, and this information needs to be extracted from proteomics experiments directly and cross-referenced with other relevant data sources. Based on Phase I results, we will implement these specifics in a novel systems proteomics platform based on MetaCore™”.

In the scope of Phase II, GeneGo will work in collaboration with Professor Austin Yang’s group from the University of Southern California, Rosetta Biosoftware, Inc. and the Michigan Proteome Consortium.

“We are happy to work with GeneGo on systems proteomics”, said Dr. Austin Yang. “One of the major issues facing most proteomics laboratories now is how to establish a proper bioinformatics workflow and how to adequately validate and interpret their proteomic results. Unfortunately like most “omics” analyses, because hundreds or thousands of proteins are examined in a single experiment, it is very difficult to evaluate the biological significance or resolution of any given proteomics analysis. Two years ago, we decided to incorporate GeneGo’s MetaCore™ into our proteomics data analysis workflow. By integrating the conventional proteomic analysis with a well-annotated network or pathway analysis system such as MetaCore™, we are able to quickly and subjectively evaluate our proteomic results with high confidence. For instance, recently, we have used this combination of bioinformatic and mass spectrometic approaches to address the roles of amyloid in altering synaptic signaling pathways in Alzheimer’s disease”.

Download this press release in PDF format.

APPLIED BIOSYSTEMS AND GENEGO COLLABORATE TO ADVANCE UNDERSTANDING OF TISSUE GENE EXPRESSION

GeneGo Integrates Applied Biosystems Tissue Gene Expression Database into its MetaCore™ Data Mining Platform

Foster City, Calif. and St. Joseph, Mich., August 3rd, 2006 – Applied Biosystems, an Applera Corporation business, and GeneGo, Inc., a leading provider of software and databases for systems biology, today announced a collaboration designed to enhance researchers’ ability to study differential gene expression in biological pathways. As part of the agreement, GeneGo has integrated the Applied Biosystems Tissue Gene Expression Database into its MetaCore™ data mining platform.

The companies said the integration of this proprietary data into MetaCore™ is expected to save researchers both time and costs that would otherwise be required to generate comparable comprehensive and high-quality curated data. The combined solution facilitates microarray experiments, such as comparing gene expression changes in normal versus diseased or treated human tissues.

The Tissue Expression Database, created using the Applied Biosystems Expression Array System and Human Genome Survey Microarray, is a proprietary dataset of genome-wide gene expression values from 31 normal tissues and a Universal Human Reference RNA. This extensive dataset can serve as a baseline reference for microarray results and a source for identifying tissue-specific genes. Applying highly sensitive chemiluminescent technology, advanced bioinformatics, and a combination of public and proprietary data, the Applied Biosystems Expression Array System can detect more genes with greater specificity and sensitivity than other commercially available microarray platforms.

“Organ, tissue and cell type specificity are extremely important in human and other mammalian gene expression analysis,” said Tatiana Nikolskaya, chief scientific officer and founder of GeneGo. “The Applied Biosystems Tissue Expression Database is high quality, standardized and very well annotated data. We have integrated it as a tissue expression filter in our latest product release to replace the publicly available, but less consistent, UniGene data, and look forward to collaborating on additional ways to leverage our complementary solutions.”

MetaCore™ is used by major pharmaceutical companies and numerous academic institutions for target selection and validation, identification of biomarkers for disease states and toxicology analysis. By enabling the visualization and analysis of complex experimental data in an integrated manner, the solution is designed for systems biology applications. MetaCore™ is based on a comprehensive, manually curated database of human biology, diseases, toxicology and bioactive chemistry and is designed for analysis of gene expression, genetic variations, and proteomic and metabolite profiles. Such integrated analysis helps accelerate the drug discovery and development process and also helps eliminate drug candidates that will have harmful side effects or interactions before they are tested in humans.

“GeneGo has a strong track record of integrating best-of-class technologies and data into its software platform to support emerging systems biology applications,” said Carl Hull, vice president for the sequence detection system and microarray business units of Applied Biosystems. “This collaboration represents a mutually beneficial way to support our respective customers in their endeavors to turn their valuable data into meaningful information in the drug discovery and development process.”

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems’ products also serve the needs of some markets outside of life science research, which we refer to as “applied markets,” such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of over $1.9 billion during fiscal 2006. The Celera Genomics Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers. Celera Genomics maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera Genomics is also discovering and validating therapeutic targets, and it is seeking to develop therapeutic products based on these discovered targets through strategic partnerships. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com.

Download this press release in PDF format.

GALAPAGOS LICENSES METACORE™ FROM GENEGO

St. Joseph, Michigan, August 1st, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Galapagos NV, a genomics-based drug discovery company, will be using the integrated software suite MetaCore™ for its internal research across several disease areas including osteoporosis, osteoarthritis and rheumatoid arthritis.

"We were satisfied with the demonstrated capabilities and quality of data obtained through MetaCore™,” commented Dr. Graham Dixon, Senior Vice President of Drug Discovery at Galapagos. “We have already identified and validated novel, proprietary targets using our adenoviral technology platform in bone and joint diseases; applying MetaCore™ to this target set could allow us to gain valuable insights at the system level thereby improving our understanding of the underlying disease biology and increasing our speed and success in finding new drugs against these targets."

“We are very pleased to welcome Galapagos as a new customer,” said Julie Bryant, Vice President of Business Development at GeneGo. “Over the last year, systems analysis of biological data has become mainstream, rather than a niche application, for high volume high throughput genomics labs. The new customization tools and expansion of knowledge content in disease areas make MetaCore™ applicable for focused research programs at specialized drug discovery companies. We are proud that Galapagos has selected MetaCore™ in the competitive market of pathways tools.”

Download this press release in PDF format.

GENEGO AND ELSEVIER MDL COLLABORATE TO PROVIDE SEAMLESS ACCESS TO COMPOUND DATABASES, PATENTS, LITERATURE AND PATHWAYS

St. Joseph, Michigan, July 20th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis and Elsevier MDL, a leading provider of scientific content, informatics framework and workflow applications for pharmaceutical research, announced the collaboration. The latest version of GeneGo’s data mining platform MetaCore™ 4.0 will be seamlessly integrated with the MDL® suite of databases via the DiscoveryGate® content platform. Researchers will be able to identify drug targets and bioactive compounds via pathway analysis and retrieve comprehensive information on their synthesis, biological effects, commercial availability and relevant literature within one application.

"The integration of MDL® databases with GeneGo's pathways information systems enables scientists to bridge the gap between cell biology and organic chemistry," comments Steve Young, Director of MDL Content Strategy. "For the first time, biologists will be able to quickly review cheminformatics data of small molecules involved in biological pathways and chemists will be able to view molecular pathway information related to their lead compounds."

“Lately, a number of customers approached us with requests for functional analysis of the effects of drug-like compounds rather than genomic data,” says Julie Bryant, VP Business development at GeneGo. “Although pathways and network analysis of bioactive compounds is a common practice in MetaCore™, we partnered with Elsevier MDL for in depth coverage of literature and patentderived information relevant for compounds. We are very pleased to be working with Elsevier MDL, the market leader in medicinal chemistry knowledge databases, Integration with the Elsevier MDL chemistry space opens up new applications for our products in medicinal chemistry, including high-throughput and high-content screening, hit selection and validation, lead development programs and chemogenomics.”

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information visit www.elsevier.com.

Download this press release in PDF format.

REPRODUCTIVE MEDICINE ASSOCIATES OF NEW JERSEY ENTERS MULTI YEAR AGREEMENT WITH GENEGO TO ACCESS METACORE™

St. Joseph, Michigan, July 13th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Reproductive Medicine Associates (RMA) of New Jersey have licensed MetaCore™ to use for research and in their clinic. Primarily, MetaCore™ will be used for analysis of gene expression data from individual human oocytes and blastomers. It was important for RMA that MetaCore™ has comprehensive curated content in the area of reproduction and is capable of concurrent analysis of multiple patients’ datasets.

”We are pleased to have acquired this excellent research tool from GeneGO. MetaCore™ will increase our ability to translate research discoveries into clinical applications that will improve the quality of life for patients with infertility," said Dr. Nathan Treff, Principle Investigator of Molecular Biology at RMA of New Jersey.

“We are very pleased to see our tools licensed by RMA”, said Julie Bryant, Vice President of Business Development at GeneGo. “MetaCore™ has been applied extensively in the area of reproductive medicine by several pharmaceutical companies and academic groups, but this is the first time it will be used by health care practitioners. This is very encouraging as our ultimate goal is to adapt systems data analysis technology to the needs of doctors and individual patients.”

Download this press release in PDF format.

SIENA BIOTECH EXPANDS METACORE™ LICENSE FROM GENEGO

St. Joseph, Michigan, July 5th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Siena Biotech has expanded the number of MetaCore™ licenses obtained from GeneGo. MetaCore™’s technology platform’s capacity to integrate multiple data types including proteomics and chemogenomics data was valued by Siena Biotech together with the quality of content in neurological diseases.

“We appreciate MetaCore™’s flexibility and GeneGo’s ability to quickly implement customer feedback,” said Dr. Georg C. Terstappen, Vice President Discovery Research, of the Italian Company. “GeneGo and Siena Biotech in their respective fields are leading the way in pathway proteomics: we expect advantages for both companies form this collaboration.”

“We are very pleased to expand our relationship with Siena Biotech” said Julie Bryant, Vice President of Business Development at GeneGo. “We are seeing more of our customers expanding the scope of data types analyzed in MetaCore™ in their R&D efforts. MetaCore™ is well equipped for this with its capacity to concurrently visualize, score and process gene expression, proteomic, metabolomic and compound data.”

Download this press release in PDF format.

NHLBI EXPANDS THEIR METACORE™ LICENSE TO COVER NHLBI, CORE, CIT AND CRITICAL CARE MEDICINE DEPARTMENT

St. Joseph, Michigan, June 27th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that their multi year agreement with NHLBI will be extended and expanded to cover National Heart, Lung and Blood Institute core microarray group, the Center for Information Technology and the Critical Care Medicine Department of the NIH Clinical Center. MetaCore™ will also be used throughout their new systems biology group and it will be an integral part of their development.

The NHLBI Microarray Core supports NHLBI investigators conducting research with the ultimate goal of understanding the pathophysiology of human diseases employing high throughput technologies. The large amount of data generated from such experimentation requires complex analytical tools for efficient data capture, analysis and interpretation of results. As a central part of its role, the core provides computational and research tools to investigators in NHLBI, CIT and CCMD and helps them expand their ability to conduct genomic research through new techniques mapping gene expression data to metabolic and signaling pathways. Currently investigators sift through large gene lists trying to decipher which pathways are affected. GeneGo’s MetaCore™ data mining software will provide factual, statistical, visual and machine learning techniques to rationalize the extensive changes in gene expression due to experimental conditions or disease processes, and DNA sequence variations. There are currently more than fifty projects in the core using Affymetrix technology that will be directly improved by access to this software. It is hoped that the application of the MetaCore™ analysis program would help decipher the key molecular mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicines.

“We have enjoyed working with NHLBI over the years and we look forward to further expand these relationships with a larger group at the center,” said Julie Bryant, Vice President of Business Development at GeneGo. “The field of functional data mining is evolving very rapidly, and collaborations with the leading academic institutions help us to be on top of state of art technology. MetaCore™ is a very dynamic platform, and the feedback from collaborators is essential in its development.”

Download this press release in PDF format.

BOEHRINGER INGELHEIM LICENSES METACORE™ FROM GENEGO FOR TOXICOGENOMICS STUDIES

St. Joseph, Michigan, June 20th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Boehringer Ingelheim has licensed its data mining suite, MetaCore™, primarily for toxicogenomics research. MetaCore™ is based on a comprehensive, manually curated database of human biology, diseases, toxicology and bioactive chemistry.

“Toxicogenomics is one of the main applications of MetaCore™, and we pay a lot of attention to the field in product development.” said Julie Bryant, Vice President of Business Development at GeneGo. “We manually curate all major toxicity journals and develop tools and workflows specifically for the analysis of toxicogenomics datasets; the work is partly sponsored by an NIEHS grant. MetaCore™ was featured in many posters and presentations at the recent Society of Toxicology meeting in San Diego, and is applied by a growing number of toxicogenomics groups in industry and academia.”

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 45 countries and about 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending approx one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com

Download this press release in PDF format.

GENEGO'S METACORE™ DATA MINING PLATFORM NOW FULLY-COMPATIBLE WITH AGILENT'S GENESPRING GX BIOINFORMATICS SOLUTION

St. Joseph, Michigan, June 6th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced the ability to integrate GeneGo’s MetaCore™ and Agilent Technologies Inc.’s GeneSpring software applications. Users of both will enjoy the interoperability between the two systems as well as the seamless workflow for statistical and functional analysis of gene expression data. Agilent’s GeneSpring is a widely used bioinformatics solution for microarray analysis and data management. MetaCore™ is the leading functional data mining platform designed for the analysis of different types of experimental data in the context of pathways, networks, cellular processes, diseases and toxic categories.

“With this relationship, we respond to multiple customer requests for integration with GeneSpring,” said Julie Bryant, vice president of Business Development at GeneGo. “GeneGo has an open, market-driven partnering philosophy, and we are happy that Agilent has a similar viewpoint. We look forward to receiving more customer feedback and further developing our systems’ interoperability.”

“The use of informatics to enable life science research has changed dramatically in the last 18 months,” said Jordan Stockton, Agilent Informatics marketing manager. “Today, researchers demand applications that allow them to pool evidence from as many sources as possible. The integration of GeneSpring and MetaCore allows leading scientists to rapidly synthesize information about pathways and molecular interactions with those from microarray technologies.”

Download this press release in PDF format.

PEAKADILLY LICENSES METACORE™ FROM GENEGO

St. Joseph, Michigan, May 15th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Peakadilly NV, Belgium, has licensed MetaCore™ for use in proteomics research. MetaCore™ will be available via the intranet to Peakadilly. It was important to Peakadilly that MetaCore™ content covers multiple levels of protein interactions from extra cellular stimuli through signaling to core metabolism and that MetaCore™ is well designed for proteomics research.

"We were impressed by the quality of the content and unique capabilities of the visualization and analysis software in MetaCore™," said Dr Koen Kas, CSO of Peakadilly.

"We are very happy that Peakadilly, well known for its innovative and high performance proteomics technologies, has chosen MetaCore™ as a functional analysis engine. We will be working closely with them as we further develop our proteomics offering," said Julie Bryant, Vice President of Business Development at GeneGo. "Compared to genomics, proteomics data is more complex, yet they provide unique insights about active cell machinery. Proteomics data mining is an important area in our technology development and one for which we have been awarded government grants."

About Peakadilly

Peakadilly was founded in late 2004 to exploit the protein biomarker discovery technology developed at VIB and the University of Ghent. In this short time, it has successfully implemented the technology and won revenue generating projects with big pharma. It applies the technology both to third party projects and to its own projects for developing a new generation of diagnostics and pharmacodiagnostic products.

Download this press release in PDF format.

GENEGO AND XB TRANSMED SOLUTIONS PROVIDE INTEGRATED SOLUTIONS TO THE TRANSLATIONAL MEDICINE MARKET

St. Joseph, Michigan, April 24th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology and XB TransMed Solutions, a translation medicine software and services company, today announced that their flagship products, MetaCore™ and XB-BioIntegration Suite (XB-BIS) are fully integrated. Mutual customers can capture, manage and mine integrated clinical, preclinical and molecular data in its various forms and statistically analyze data associations using XB-BIS, and functionally analyze the associated results in the context of biological pathways, networks, cellular processes and disease networks in MetaCore™.

"XB-BIS has been developed to fulfill the need in translational medicine for efficient data capture, management, analysis and reporting in an intuitive workflow that resembles the natural translational path from early hypothesis generation to validation and application in the areas of clinical diagnostics and intervention" said Dr. Craig Webb, Program Director for Translational Medicine at the Van Andel Institute. "Integration with the MetaCore™ systems biology toolsets permits the user to seamlessly integrate back and forth between expanding knowledge and enhanced application."

"Over the past year, we have seen an increasing demand in systems biology solutions from the clinical trial market," said Julie Bryant, Vice President of Business Development at GeneGo. "Understanding the differences of drug effects on individual patients is a very challenging task, which requires state of the art tools in both translational medicine and functional data mining. We are very pleased to join forces with XenoBase inventors Dr Craig Webb and Dr. Jeremy Miller at the Van Andel Institute to develop analytical workflows for the clinical environment."

About XB TransMed Solutions

XB TransMed Solutions, was founded as a next generation life science application and services company with headquarters in Grand Rapids, Michigan. The focus of XB TransMed Solutions is to provide leading edge software and service solutions expediting the complete life science work process from novel discovery to clinical application in an integrated environment. XB Trans Med markets its Bio-Integration Suite as a fully integrated biological and medical informatics solution that allows users to generate, refine, and validate causal hypotheses across disparate data sets. The purpose is to provide a complete solution in the area of translational biomedical research, whereby bench-side research can rapidly lead to discoveries that can be readily applied to bedside medicine.

XB Bio-Integration Suite are trademarks of XB TransMed Solutions, LLC

Download this press release in PDF format.

INFORSENSE® AND GENEGO JOIN FORCES TO DELIVER INTEGRATED PATHWAY-BASED WORKFLOWS TO ENABLE SYSTEMS BIOLOGY RESEARCH

• Integration of InforSense and GeneGo Products to Provide Flexible, High-Throughput Pathway-centric Data Analysis
• GeneGo joins InforSense's Open Workflow Partner Network as 20th Member

London, UK and Cambridge, MA, USA, April 11th, 2006 - InforSense Ltd., the leader in integrative analytics platforms, today announced that the company has joined forces with GeneGo, a leading provider of systems biology tools and databases. The companies are integrating their technologies to allow researchers to better probe their data and share their work process across different research domains. GeneGo has also joined the InforSense Open Workflow Partner Network.

The integration of GeneGo's unique reference system for curated pathway analysis and InforSense's integrated, interactive workflow-based data mining technology allows researchers to query their data and share their results across the research and development value chain. In addition to the integration of InforSense KDE and MetaCore™, which is already available, the companies are in the process of integrating InforSense KDE with both MetaDrug™ and MetaBase™. Customer feedback supports integration of GeneGo's software suite with the proven InforSense workflow technology, as researchers will be enabled to bridge domains such as genomics and metabolomics with high confidence data using a systems biology approach. In addition, users will be able to annotate pathway data with experimental results and clinical data and thereby better predict patient outcomes.

"The collaboration between InforSense and GeneGo will deliver to thousands of users the needed environment for leveraging high-throughput biology and chemistry data more effectively for better and faster decision-making within the life science industry," said Julie Bryant, Vice President of Business Development of GeneGo. "InforSense workflows enable life science researchers to compose and execute scientific analyses quickly and easily without programming, sharing both methods and results with co-workers."

"MetaCore has grown to become a key component in the research toolbox in the life sciences, particularly within the pharmaceutical industry, and we are pleased to have the opportunity to work with GeneGo," commented Dr. Jonathan Sheldon, Chief Scientific Officer, InforSense. "The integration of pathway analysis with InforSense KDE is a key component of our multidisciplinary analytics platform for Systems Biology."

About InforSense

InforSense Ltd., the leader in integrative analytics, enables organizations to orchestrate and optimize their business-critical decision-making processes. Leading pharmaceutical and biotechnology, consumer goods, financial services companies, and research institutes are using the company's flagship product, InforSense KDE, to enhance productivity across life science R&D, healthcare, and business analytics. The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts.

About InforSense KDE

Using InforSense KDE, enterprises rapidly integrate and deliver virtually any data source, analytic software tool, service or application within a single informatics framework. Users link these components via visual workflows to dynamically answer any question using their data, however complex or transient. Organizations can also mine their analytical processes to discover and deploy expertise and best practices. InforSense KDE provides an open, extensible service-oriented architecture, built using industry standards including J2EE, XML, and WSDL. InforSense IOE is a state-of-the-art solution for enterprise-wide integrative analytics using Oracle's advanced information management and processing capabilities.

About InforSense Partner Network

The InforSense Partner Network provides interoperability between industry leading technologies via InforSense KDE. Mutual customers benefit from proven integration between their tools of choice across scientific and business analytics via an intuitive visual workflow interface.

For more information visit www.inforsense.com

InforSense, TextSense and the InforSense logo are registered trademarks of InforSense Limited. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

Download this press release in PDF format.

BERLEX SIGNS LICENSE AGREEMENT WITH GENEGO

St. Joseph, Michigan, March 13th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that it has entered into a licensing agreement with Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), for MetaCore™. The license provides researchers at Berlex and its German parent company with use of the MetaCore™ platform for analysis of gene expression, proteomic, metabolic and other high-throughput data in multiple therapeutic areas, including oncology, and in diagnostic applications.

"We are very pleased to bring MetaCore™ into our research," said Hugh Salamon, senior computational biologist, Berlex. "It is essential to exploit curation of scientific findings given the large body of knowledge relevant to therapeutic research. GeneGo is providing us with an important view of current knowledge of mammalian signaling, metabolism, drugs and diseases through the MetaCore™ platform."

"We are very pleased that researchers at Berlex Biosciences, the US research center for Berlex, will be using MetaCore™ and to have the company as a GeneGo customer," said Julie Bryant, Vice President of Business Development at GeneGo. "Berlex researchers will be among more than 140 unique accounts and thousands of users. Feedback from such partnerships help us enhance MetaCore™ as a versatile, multi-purpose data mining tool applicable in diverse life science projects.

Download this press release in PDF format.

GENEGO EXPANDS LICENSE WITH JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT TO INCLUDE METABASE™ ACCESS

St. Joseph, Michigan, February 20th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Johnson & Johnson Pharmaceutical Research & Development, (J&JPRD), a division of Janssen Pharmaceutica N.V., has extended their MetaCore™ license to now include MetaBase™, a database J&JPRD will primarily use for biomarker discovery.

"We are pleased to have this relationship extended," said Julie Bryant, Vice President of Business Development at GeneGo. "We look forward to enhancing our collaboration with the MetaBase™ integration."

Download this press release in PDF format.

GENEGO AND GENEDATA COMBINE FORCES TO PRODUCE ULTIMATE ENTERPRISE PLATFORM

St. Joseph, Michigan, February 13th, 2006 - GeneGo Inc. and Genedata AG, providers of computational solutions for systems biology and biomarker discovery, announce that their computational systems have successfully been integrated to support a seamless data analysis workflow. The workflow supports target selection and validation as well as diagnostic and biomarker applications.

"Today, drug discovery scientists handle very complex "genome wide" experimental datasets. To cope with such complexity they need a variety of analytical approaches and databases not available from any single source. Therefore, cooperation between computational biology specialists is logical and beneficial for end users", explained Julie Bryant, Vice President of Business Development at GeneGo Inc.

GeneGo's flagship analytical suite, MetaCore™ combines a manually curated database of clinical and pre-clinical biology information and bioactive compounds with comprehensive pathways and network analyses. Bryant added, "MetaCore™ can now be connected with Genedata Expressionist® and Genedata Phylosopher®, so mutual customers will be able to move iteratively between the software systems seamlessly and inter-operatively".

"Genedata's open and scalable architecture provides a strong basis for integration with client and third party content", says Dr. Daniel Keesman, CEO of Genedata AG. Expressionist enables omics data and associated information to be imported, processed and analyzed in an automated and repeatable workflow. Phylosopher has been integrated closely with MetaCore's visualization tools to identify and prioritize pathways affected by disease. The integrated solution achieves unrivaled standards in research information management and decision support. Dr. Keesman added, "This integration has been customer-led and helps scientists place their results in biological context, thus deriving maximum benefit from experimental data".

Download this press release in PDF format.

MERCK EXTENDS GLOBAL ENTERPRISE LICENSE OF METACORE™ AND METADRUG™ FOR TWO ADDITIONAL YEARS

St. Joseph, Michigan, January 9th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck & Co., Inc. has extended its global enterprise agreement for two additional years.

Merck researchers around the world will continue to use the MetaCore™ data mining suite in research and development activities. The researchers will also retain direct access to MetaBase™, a comprehensive database of mammalian protein interactions, signaling and metabolic pathways, bioactive compounds, and diseases manually curated by GeneGo from full text experimental literature. MetaCore™ and MetaBase™ have been integrated with Merck's discovery informatics platform and are leveraged across multiple therapeutic areas.

"Merck has been a great partner, and we have enjoyed interacting with their scientists. As a result of this collaboration, we have developed a number of new data analysis and visualization features now available in MetaCore™. We will continue to encourage this high level of communication as we move forward in 2006," said Julie Bryant, VP business development. "The field of functional data analysis is maturing rapidly, and it is crucial for us to work closely with state-of-art research teams, such as those at Merck."

Download this press release in PDF format.

SCITEGIC'S ISV PARTNER PROGRAM WELCOMES TWENTIETH MEMBER

SAN DIEGO, CA, January 9, 2006 - SciTegic, the leader in data pipelining and workflow tools announced today that four new members have joined its Independent Software Vendor (ISV) partner program. The program's aim is to compile a collection of high value life sciences applications to address customer needs for increased software interoperability. Through new collaborations with ACD/Labs, Bio-Rad, GeneGo, and Partek, scientists in drug discovery will obtain access to new, integrated software products that will help them solve more complex research problems in a more efficient manner.

"We are pleased to see a rapidly growing community adopt the Pipeline Pilot platform for life sciences software deployment", says Mathew Hahn, Vice President and General Manager of SciTegic. "By promoting partnerships with key scientific software vendors, we allow our customers to leverage existing, specialized software solutions in order to increase their R&D productivity."

"Our joint customers will be able to access ACD/Labs' PhysChem and Nomenclature batch software (www.acdlabs.com) from within SciTegic's Pipeline Pilot framework, leading to more efficient and repeatable discovery processes," says Antony Williams, Vice President and Chief Science Officer of ACD/Labs.

"The combination of our KnowItAll® technologies (www.knowitall.com/adme) for in silico ADME/Tox with SciTegic will allow drug discovery researchers to more accurately predict key properties for potential drug candidates, thus accelerating the drug discovery process," says Gregory M. Banik, Ph.D., General Manager of Bio-Rad Laboratories, Informatics.

"We are excited to deliver our technology as part of SciTegic's Pipeline Pilot platform," says Julie Bryant, Vice President of Business Development of GeneGo. "Joint customers will be able to increase their research efficiency by rapidly incorporating pathway information in their workflows."

"We are pleased to join SciTegic's ISV program," said Tom Downey, President and CEO of Partek, "as it allows us to bring together the data workflow capabilities of Pipeline Pilot with the statistics and interactive visualization capabilities that our software offers, allowing life sciences researchers to make better decisions."

Download this press release in PDF format.

TNO EXPANDS RELATIONSHIP WITH GENEGO TO COVER ALL MAJOR EUROPEAN NUTRIGENOMICS INITIATIVES

St. Joseph, Michigan, November 14th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, announced today the expansion of their partnership with TNO (the worlds largest independent nutrition research institute, www.tno.nl), the Dutch Nutrigenomics Consortium and the European Nutrigenomics Organization (NUGO, www.nugo.org), together forming a group of 23 Universities and Research Institutes active in the area of nutrigenomics. TNO and the NuGO consortium members will be using MetaCore™ version 3.0 in multiple research areas on nutrition, metabolism and related diseases. The latest version of MetaCore™ will allow them to build combined metabolic/signaling networks from virtually any kind of experimental data. They will be able to share experiments and results between any other NuGO consortium member and TNO's employees using a novel information management module in MetaCore™.

"At TNO, we have worked with Metacore™ for one year now; both the tool and the interaction with GeneGo were highly satisfactory," said Dr Ben van Ommen, responsible for the nutrigenomics activities at TNO and director of NuGO. "In the area of nutrigenomics, the interaction between the transcriptome and metabolome are crucial. Upon our request, GeneGo has extended its software with a metabolomics parser, allowing simultaneous visualization of gene expression and metabolite concentration in the same pathways. Nutrition science experiences a rebirth now that we can combine physiology with molecular details in the new area of nutrigenomics and nutritional systems biology, and adequate bioinformatics is one of the main limiting factors to success."

"We are very excited about this expanded agreement as there will now be 23 academic institutes in Europe using MetaCore™ under this agreement", said Julie Bryant, VP of business development at GeneGo. "Our collaboration with TNO researchers helped us to adjust MetaCore™ for the needs of nutritional science which requires comprehensive coverage of human metabolism and understanding the connectivity between metabolic and signaling pathways. We have also developed the first metabolic parser which enables import of metabolomics data, its visualization and analysis along with molecular data in the framework of pathways and networks."

Download this press release in PDF format.

VELCURA THERAPEUTICS AND GENEGO ENTER MULTI YEAR AGREEMENT

St. Joseph, Michigan, November 9th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Velcura Therapeutics, Inc. has licensed MetaCore™, GeneGo's manually curated pathways database and data mining suite. All Velcura employees will have access to the MetaCore™ database and suite of software tools for three years to focus on bone related disease research. Velcura researchers will be using MetaCore™ for analysis of gene expression, proteomic, and other data related to human bone formation.

"We spent quite some time evaluating systems biology platforms and were impressed by the depth and breadth of the MetaCore™ knowledge base." said Dr. Daniel Chagnovich, Director of Research Operations for Velcura. "MetaCore™ has impressive coverage of signaling and metabolic pathways and in-depth disease and tissue-specific data that is invaluable for our research. In addition, MetaCore™ has a flexible and powerful front-end that allows our bench scientists to integrate multiple data streams and algorithms to fully mine our bone therapy data."

"We are very pleased to have Velcura as a new GeneGo customer," said Julie Bryant, Vice President of Business Development at GeneGo. "High-throughput experimentation matures fast, and nowadays researchers deal not only with gene expression, but also individual DNA variability, protein abundance and isoforms content, changes in body liquid metabolic profiles and high content drug screening data. To be able to visualize and analyze such diverse datasets, we have built a comprehensive database of direct interactions between genes, proteins, enzymes, metabolic by-products and cell-regulators in human and other mammals. Velcura researchers will be able to directly access this content and use it in projects via their MetaCore™ license."

Download this press release in PDF format.

FOR THE FIRST TIME, SIGNALING AND METABOLIC NETWORKS CAN NOW BE MERGED WITH GENEGO'S METACORE™ VERSION 3.0

St. Joseph, Michigan, October 31st, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, announced today the major new release of its flagship data mining platform MetaCore™ 3.0. In the new version, scientists can for the first time build combined signaling/metabolic networks from virtually any kind of experimental data. This breakthrough may provide a quantum leap in the resolution of functional analysis of gene expression, proteomics, metabolomics, high content screening (HCS), siRNA and other types of experimental data. MetaCore™ 3.0 also features a unique parser for visualizing metabolomics data in the context of pathways with seamless connectivity between networks, canonical pathways, cellular processes and human diseases. The new version also adds a sophisticated enterprise-wide data management and user access system and disease specific networks.

"We believe that in this new version, we solved a major problem in functional data analysis - namely the uncoupling between signaling and effector networks in complex systems," said Dr. Tatiana Nikolskaya, Chief Scientific Officer, President and Founder of GeneGo. "A living cell reacts to stimuli largely by changing its core biochemistry, and many metabolites serve as signaling molecules and mediators. Genome-wide formalization of the whole process from receptor-ligand interactions to activation of certain metabolic pathways is key in the understanding of complex conditions such as diseases or drug effects. Yet, signaling and metabolic pathways so far were largely not connectible even for the best studied yeast. Now, we have completed this project for human and other mammals. With integration of metabolic and signaling networks, as well as receptor-ligand interactions, the spectrum of resolution in MetaCore™ covers all levels from cellular processes to individual proteins small molecules interactions."

"In practical terms, this means that our customers can now analyze in one system multiple datasets which would be incompatible in any other environment, for instance mass spec metabolic data from human blood generated in clinical trials with pre-clinical rat expression arrays and cell culture siRNA experiments", said Julie Bryant, VP of business development at GeneGo. "Think about cross-validation of metabolic biomarkers and drug mode of action studied in animal systems and screening data. MetaCore™ 3.0 is a common environment for both biologists and chemists throughout the whole drug discovery pipeline. We have also addressed sharing of experiments, knowledge and analysis with a sophisticated enterprise account and experiment management system with hierarchical access to shared accounts, data and results exchange and annotation through e-notes."

Download this press release in PDF format.

THE U.S. FOOD AND DRUG ADMINISTRATION WILL USE GENEGO'S METACORE™ FOR "OMIC'S" RESEARCH AND REVIEWING OF GENOMICS DATA

St. Joseph, Michigan, October 10th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the U.S. Food and Drug Administration (FDA) have licensed MetaCore™ for "OMIC's" research and reviewing of genomics data. GeneGo and the FDA will also integrate MetaCore™ with ArrayTrack and make it available for FDA researchers, http://www.fda.gov/nctr/science/centers/toxicoinformatics/ArrayTrack/

The MetaCore™ platform allows scientists to concurrently visualize, map and network multiple types of data including gene expression, SiRNAi, proteomic, metabolomic, SAGE and SNP data, both from pre-clinical discovery and clinical studies.

"High throughput (HT) experimentation is increasingly important for life science research, and HT data is now included in many new drug applications submissions. The analysis of such complex datasets requires novel systems biology tools, such as MetaCore™," said Dr Tatiana Nikolskaya, founder and CSO of GeneGo Inc. "One important issue in FDA submissions is compatibility and cross-referencing of multiple types of pre-clinical and clinical data, which are collected at different times by different research groups. MetaCore™ offers both a functional framework and analytical engine for this."

"Working with the FDA is very important for GeneGo and we are very pleased to announce this relationship," said Julie Bryant, Vice President of Business Development at GeneGo. "Since MetaCore™ is already being applied in drug discovery by our pharmaceutical customers for a couple of years now, it is logical that it will be also used on the regulatory side as well."

GeneGo has assembled the world largest manually curated database of human biology and medicinal chemistry, which includes genes, proteins, natural ligands, metabolites, drugs and diseasesfrom millions of literature findings.

About Array Track

ArrayTrack provides an integrated solution for managing, analyzing, and interpreting microarray gene expression data. Specifically, ArrayTrack is MIAME (Minimum Information About A Microarray Experiment) supportive for storing both microarray data and experiment parameters associated with a pharmaco- or toxico- genomics study. Many statistical and visualization tools are available with ArrayTrack. ArrayTrack also provides a rich collection of functional information about genes, proteins and pathways for biological interpretation. The primary emphasis of ArrayTrack is the direct linking of analysis results with functional information for facilitating the interaction between the choice of analysis methods and the biological relevance of analysis results. Using ArrayTrack, user can easily select a statistical method applied to a stored microarray data to determine a list of differentially expressed genes and the gene list can be directly linked to pathways and gene ontology for functional analysis.

Download this press release in PDF format.

GENEGO'S METACORE™ SOFTWARE APPLICATION ACHIEVES GENECHIP-COMPATIBLE™ STATUS WITH AFFYMETRIX' GENECHIP® MICROARRAY PLATFORM

MetaCore for easy, intuitive visualization and analysis of expression data on pathways and networks

St Joseph, MI, September 19th , 2005 - GeneGo today announced that its MetaCore software application has achieved GeneChip-compatible™ status with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has joined the Affymetrix GeneChip-compatible™ Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development. As a GeneChip-compatible software provider, GeneGo is committed to seamlessly integrating its MetaCore platform with the Affymetrix GeneChip platform.

MetaCore has worked with Affymetrix probe IDs since the product's launch in March 2004, alongside with a number of other conventional identifiers. Upon parsing, microarray expression data is visualized and analyzed in the context of pathways, biological networks and cellular processes, using the manually curated knowledge base of over 4.5 million findings. MetaCore supports parsing species specific arrays for human, rat, mouse, yeast, worm, fly and chicken, as well as specialty arrays such as Affymetrix tox chips. MetaCore also has the unique ability to visualize multiple gene expression, genetic and proteomic data sets concurrently.

"Affymetrix is a clear market leader in microarray technology and we make it a priority that our products work seamlessly with the content of their GeneChip microarrays. Currently, we map more Affymetrix probes on pathways and networks than any other data mining platform" said Julie Bryant Vice President of Business Development. "We work in close contact with the Affymetrix team to keep on top of their development and new products".

"Pathway analysis and annotation represents a critical link between microarray data and biomedical utility." Said Steve Lincoln, Vice President of Informatics at Affymetrix. "We are pleased to be working with GeneGo in integrating our platforms, allowing our mutual customers to get the most from their GeneChip data."

Download this press release in PDF format.

GENEGO IS AWARDED A PHASE II NIH GRANT FOR IN SILICO ASSESSMENT OF DRUG METABOLISM AND TOXICITY

St Joseph, Michigan, August 8th, 2005 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today that they have received a Phase II SBIR grant from the National Institute of General Medical Science. The grant enables the further development of a computational tool MetaDrug™ to improve the prediction of ADME and Toxicology properties of novel small molecule compounds.

"MetaDrug™ is the very first systems pharmacology platform in the market, designed primarily for small molecule discovery programs at drug companies and academic centers. Building this benchmark platform, we relied on customer feedback and our own vision for the field. Now, we are very glad that NIH agrees with our development goals," said Julie Bryant, Vice President, business development.

"Our customers particularly like the flexibility of the system which makes their version of MetaDrug™ specific to their chemistry space and informatics environment. We will continue working in this direction. New funding will also allow us to expand applicability of MetaDrug™ in other areas of biological effects of drug action such as pharmacogenomics, prediction of side effects and new therapeutic indications."

"This funding will enable us to expand the scope of MetaDrug™ integrating predictive algorithms for ADME/Tox properties, and add a database of ligand-protein interactions from other species, in addition to humans," said Dr. Sean Ekins, Vice President of Computational Biology, GeneGo. "We will develop large in vitro datasets for drug interactions with key human cytochrome P450s that will be used to build predictive algorithms to complement those currently in MetaDrug™. We also intend to integrate a novel algorithm for metabolite prediction that will allow us to highlight the important metabolites. Our approach to understanding the potential for interactions using predictive algorithms and our core strength of database generation and gene network algorithms represents a novel system for in silico assessment of drug metabolism and toxicity."

Download this press release in PDF format.

UCSD EXPANDS LICENSES OF METACORE™ FROM GENEGO TO MORE DEPARTMENTS

St. Joseph, Michigan, July 25th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that UCSD has expanded licenses of MetaCore™, GeneGo's platform for mining and visualization of high-throughput experimental data in the context of biological networks, pathways and diseases. MetaCore™ will be utilized in Schizophrenia, bipolar disorder, HIV associated neurodegeneration and Hep C infection projects as well as in the core micro array facility to explore gene expression profiles of psychotropics. MetaCore™ enables concurrent visualization and analysis of gene expression, proteomics and metabolomics data in multiple formats including LocusLink, Genbank, RefSeq, All Affymetrix arrays tags, OMIM, Unigene, SwissProt as well as other approved gene symbol IDs. MetaCore™'s content is manually curated and species specific. MetaCore™ is an easy to use program that can be accessed at the map level or by building networks on the fly choosing from one of our 8 network building algorithms.

Nicholas Schork, Professor of Psychiatry and Co-Director of the new UCSD Center for Human Genetics and Genomics says, "We and others within the UCSD Medical School are developing integrative approaches to understanding the pathophysiology of human diseases that will include, among other things, emphases on DNA sequence variation, altered gene expression, and protein perturbations, so having a tool like MetaCore™ to help synthesize information about pathways and genetic networks is absolutely crucial." "My group evaluated MetaCore™ to better understand neuropathological changes associated with Schizophrenia using our high throughput data. We felt that this software can help us understand the details of cellular changes in these disorders so we decided to license it, along with several other groups at UCSD," said Dr. Ian Everall, Professor of Psychiatry, Department of Psychiatry, UCSD School of Medicine. "We will be using MetaCore™ for a number of projects investigating the mechanisms of signal transduction downstream of GPCR and tyrosine kinase receptors. This software will help us to understand the complex physiological regulation of reproduction and glucose metabolism," said Dr. Nicholas Webster, Professor of Medicine and Director of the Genechip Miicroarray Core Facility.

"We have had a great relationship with UCSD over the past few years and are happy to expand on it", said Julie Bryant, VP of Business Development. "We are hoping that the added visibility, especially at the core facility, will give more scientists a chance to utilize MetaCore™ in their research. We plan to continue to work closely with UCSD on these and several other projects."

Download this press release in PDF format.

ROSETTA BIOSOFTWARE AND GENEGO TO OFFER INTEROPERABILITY BETWEEN THE ROSETTA RESOLVER® SYSTEM AND METACORE™

SEATTLE, Wash., and ST. JOSEPH, Mich., July 18, 2005 - Rosetta Biosoftware and GeneGo, Inc. today announced a collaboration to establish interoperability between Rosetta Biosoftware's Resolver system and GeneGo's MetaCore™ system. Researchers will be able to easily exchange data between the MetaCore™ and Resolver systems to leverage both systems' ability to analyze gene expression data and perform sophisticated pathway analysis.

The Rosetta Resolver system is a versatile and robust comprehensive gene expression data analysis system that enables research organizations to efficiently and effectively conduct life-saving discoveries and develop drugs. The MetaCore™ system is an integrated platform that includes a software suite for functional analysis of microarrays, Serial Analysis of Gene Expression (SAGE), proteomics, metabolomics and other high throughput experimental data. The platform is based on a unique, manually-curated database of human protein-protein and protein-DNA interactions, transcriptional factors, signaling, metabolism, and bioactive molecules.

"Rosetta Biosoftware's collaboration with GeneGo supports our customers' desire to analyze data in the Rosetta Resolver system in conjunction with pathway information from MetaCore™", said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware." Our mutual customers will now be able to combine the Resolver system's powerful analysis tools with the MetaCore™ system's comprehensive pathways to determine on- and off-target effects and to enrich gene expression data with biological context."

"GeneGo is pleased to be working with Rosetta Biosoftware in response to customers asking for the two companies to smoothly integrate their platforms so they can follow a daily workflow from expression analysis through to pathway analysis and visualization in an iterative easy to use manner," said Julie Bryant, vice president of business development.

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.

Download this press release in PDF format.

SIENABIOTECH LICENSES METACORE™ FROM GENEGO

St. Joseph, Michigan, July 6th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Siena Biotech has licensed MetaCore™ version 2.5, GeneGo's platform for mining and visualization of high-throughput experimental data in the context of biological networks, pathways and diseases. MetaCore™ enables concurrent visualization and analysis of gene expression, proteomics and metabolomics data in multiple formats including LocusLink, Genbank, RefSeq, All Affymetrix arrays tags, OMIM, Unigene, SwissProt as well as other approved gene symbol IDs. MetaCore™'s content is manually assembled from full text experimental articles by qualified curators. The latest release, MetaCore™ version 2.5, features multiple functions for statistical analysis of biological networks, inter-experimental comparisons, and new algorithms for pathways prioritization based on tissue specificity, sub-cellular localization, interaction types, and relevance to cellular processes.

"We tested several platforms in the systems biology marketplace and felt that MetaCore™ best suited our current needs," said Dr. Georg C. Terstappen, Vice President Discovery Research at Sienabiotech SpA. "We felt that the content was broad, deep with a high level of quality control and we can access information without having experimental data as a starting point," included Dr. Andreas Kremer, Head of Bioinformatics.

"We are happy to welcome Sienabiotech as the first Italian company on our rapidly growing list of new customers", said Julie Bryant VP of Business Development. "With fast evolution of OMICs technologies, and concurrent analysis and cross-validation of multiple data types becoming increasingly important, we emphasize such features in the new version of MetaCore™. Sienabiotech will be able to visualize and directly compare gene expression and proteomic data on the same networks and pathways maps. Our new version features over 400 static maps of canonical signaling and metabolic pathways and eight network building algorithms."

Download this press release in PDF format.

GENEGO IS AWARDED DOD GRANT FOR SYSTEMS BIOLOGY PROTEOMICS PLATFORM

St. Joseph, Michigan, June 27th, 2005 - GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today they have been awarded a SBIR grant from Department of Defense (DARPA) for the development of a systems biology suite of tools for visualization and analysis of proteomics data. In Phase I, GeneGo will adapt its data-mining platform MetaCore™ for handling a broad range of proteomics data types; connectivity of these data with other OMICs datasets; and will develop new algorithms for reconstruction of protein-state specific biological networks and pathways.

"Proteomics enables experimental analysis of protein complexes and protein-protein interactions, which carry out most cellular processes. Therefore, proteomics data is destined to play a central role among OMICs datasets characteristic for a condition," said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. "However, proteomics data is more complex and ambiguous than, for instance, microarray gene expression or DNA sequences. We know how to work with processed proteomics datasets, but it is the details such as fold, post-translational modification, sequence variation, local abundance in compartments, which define the cellular state in normal and disease. In our proposal, we emphasized these specifics as well as systemic approach to the understanding of proteomics and other OMICs datasets."

In the scope of the grant, GeneGo will work in collaboration with Associate Professor Austin Yang's group from the University of Southern California.

"Because of rapid advance of proteomic technologies and improved of mass spectrometry user interface, most laboratories can generate a very large amount of data in a rather short period of time. Thus, one of the major issues facing most proteomics laboratories now is how to establish a proper bioinformatics workflow and how to adequately validate and interpret their proteomic results. Unfortunately, like most "omics" analyses, because hundreds or thousands of proteins are examined in a single experiment, it is very difficult to evaluate the biological significance or resolution of any given proteomics analysis. Two years ago, we decided to incorporate Metacore™ into our proteomics data analysis workflow. By integrating the conventional proteomic analysis with a well-annotated network or pathway analysis program such as Metacore™, we are able to quickly and objectively evaluate our proteomic results with high confidence. Recently, we have used this combination of bioinformatics and mass spectrometric approaches to address the roles of amyloid in altering synaptic signaling pathways in Alzheimer's disease," said Professor Yang.

Download this press release in PDF format.

INVITROGEN CREATES UNIQUE SYSTEMS BIOLOGY CONCEPT THROUGH INTRODUCTION OF I-PATH

225 original maps identifying and visualizing biologic pathways, available free to researchers

Carlsbad, CA. and Philadelphia, PA., June 20, 2005 - Invitrogen Corporation (NASDAQ - IVGN), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, unveiled its latest concept in bioinformatics and systems biology with the launch of i-Path at the BIO 2005 international conference.

A new resource for scientists worldwide, i-Path consists of 225 high-level, annotated, validated original maps of human cell signaling and metabolic pathways compiled by GeneGo Inc, a leading provider of databases and software for systems biology. Invitrogen scientists have further identified the specific antibodies, siRNA, full-length DNA clones and other biological molecules involved in cell function and disease on these maps. The system enables researchers to visualize molecular interactions in a highly graphical, user-friendly, interactive format and will be available to scientists free of charge on Invitrogen's Web site.

"i-Path continues our tradition of providing enabling, Web-based technologies to support researchers throughout their experiments," said Michael Stapleton, Vice President & General Manager eCommerce and Bioinformatics for Invitrogen. "Building on a rich history that includes the acquisition of InforMax, Invitrogen has moved powerful design and analytic capabilities into the mainstream of science by coupling these systems with familiar research tools and making them freely available through our Web site."

i-Path includes maps of pathways that cover more than 2,500 genes - all of them human -of interest to biotech and pharmaceutical researchers. These include 171 signal transduction pathways representing the majority of known proteins involved in these processes and 54 metabolic pathways representing a significant number of genes involved in drug metabolism. The maps were created and annotated by a team of more than 40 scientists using information from thousands of scientific papers and validated with the accuracy and authenticity of pathways based on the latest scientific consensus. i-Path will also provide a time-saving link to reagents, kits and other Invitrogen research products related to the study of each molecule detailed in the pathway maps.

"With Invitrogen's deep portfolio of research capabilities we are in a unique position to support systems biology as a driver of life science research and drug discovery," said Gregory T. Lucier, Chairman and CEO of Invitrogen Corporation. "With our latest offerings we are solidifying our Website as the center of scientific conversation about the nature, structure and utility of biologic pathways." Details about Invitrogen's new bioinformatics initiative will be made available at a news conference at the BIO 2005 conference, 2pm, Monday, June 20th in room 203B Demonstrations will also be available the Invitrogen booth in the exhibit hall. i-Path will be accessible at www.invitrogen.com/ipath beginning June 20, 2005.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery, including functional genomics, proteomics, bio-informatics and cell biology, placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, Calif., and conducts business in more than 70 countries around the world. The company globally employs approximately 4,500 scientists and other professionals, and had revenues in excess of $1 billion in 2004. Information about Invitrogen is available on the Web at www.invitrogen.com.

Forward-Looking Statements

Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Invitrogen's intent to provide i-Path content free of charge on its Web site; 2) Researchers' ability to visualize their pathway of interest; 3) Invitrogen's intent to link its technology portfolio to molecules identified in i-Path's maps; 4) Invitrogen's Web site becoming the center of scientific conversation around the nature, structure and utility of biologic pathways. Potential risks and uncertainties include, but are not limited to, the risks: a) Changing market conditions and restrictions on providing scientific content b) Availability and range of pathway content; c) Access to matching Invitrogen products from its catalog; d) Industry adoption and use of i-Path and Invitrogen's Web site, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.

Download this press release in PDF format.

GENEGO IS AWARDED NIH GRANT FOR DISEASE NETWORK ALGORITHMS

St Joseph, Michigan, June 13th, 2005 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today that they have received a Phase I SBIR grant from the National Institute of General Medical Science for development of methodologies intended for reconstruction of functional networks affected in common human diseases. In Phase I, GeneGo will generate and test novel algorithms enabling comparison of disease related OMICs datasets of different origin, based on networks topology and content.

"Analysis of human biological networks is an exciting new area of systems biology, and we are glad that our efforts are appreciated by the NIH", said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. "Common diseases have profound effects on both signaling and metabolic machinery, usually in more than one cell type. Because of this, the result detected by ?genome scale" technologies such as microarray gene expression, proteomics and genotyping, is complex and multi-level. Each data type provides only one level of information, and total reconstruction of the ?big picture" of molecular pathology is a major challenge. We will study conditional perturbations of the human interactome assembled from manually curated physical protein interactions and develop algorithms for assembly of complete functional networks, from membrane receptors to transcriptional factors and ?core effector" metabolic pathways. We will test the approach on disease datasets in collaboration with the Van Andel Research Institute".

"We are truly excited at this opportunity to collaborate with the GeneGo team. We believe that the integrated approach offered through GeneGo?s advanced computational systems will be critical in deciphering the key molecular mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicine"; said Dr. Craig Webb, a lab head at Van Andel and an advisor on the grant.

Download this press release in PDF format.

GENEGO INC. INTEGRATES ACCELRYS ACCORD TECHNOLOGY IN METADRUG™

St. Joseph, Michigan, June 6th, 2005-GeneGo Inc., a leading provider of databases and software for systems biology, announced today that they have integrated Accelrys' Accord technology in MetaDrug™, their Systems-ADME/Tox and medicinal chemistry platform.

MetaDrug™ features maps, pathways and networks for human proteins related to ADME/TOX; a database of small molecules with kinetic data for human drug metabolizing enzymes, Proprietary algorithms for rule-based metabolite prediction, highlighting of reactive metabolites, >40 QSAR models for ADME/TOX properties, descriptors relevant to ADME parsers for importing data from all major microarray platforms, SAGE, proteomics and metabolomics data; two proprietary network building algorithms; flexible visualization and data exchange tools.

MetaCore™ features a comprehensive set of maps, pathways and networks for almost all known human proteins; parsers for importing data from all major microarray platforms, SAGE, aCGH, RNAi proteomics and metabolomics data; seven proprietary network building algorithms; flexible visualization and data exchange tools.

"Integrating Accelrys' Accord technology with GeneGo's MetaDrug™, is another example of how Accelrys is looking to expand access to best-of-breed technologies to scientists in the Pharmaceutical and Biotech sector," commented Dr. Eric Jamois, Director of Business Development at Accelrys. "Combining the power of the Accord Chemistry engine with MetaDrug™'s algorithms will ultimately help enhance the data visualization and database searching capabilities of MetaDrug™."

"We are thrilled to be working with Accelrys and excited about the capabilities of our combined software for the field of Systems-ADME/Tox." said Dr. Sean Ekins, Vice President, Computational Biology at GeneGo. "It took our team several years to build tools and pathway content, proprietary algorithms for metabolite prediction and ADME/Tox QSAR models. We can now apply the Accord tools for molecule visualization and database searching capabilities within MetaDrug™."

About Accelrys, Inc

Accelrys, Inc. is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California.

Download this press release in PDF format.

NATIONAL CANCER INSTITUTE LICENSES METACORE™ SITE WIDE FROM GENEGO

St. Joseph, Michigan, May 31st, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the National Cancer Institute has licensed MetaCore 2.5™, GeneGo's platform for mining of high-throughput experimental data in the context of biological networks, pathways and diseases. All NCI researchers will now have access to MetaCore™ in house through their web browser and will be able to analyze multiple types of small to "genome scale" experimental datasets from their workstations. Based on the largest curated database of mammalian biology and physical protein interactions, the latest version, MetaCore 2.5™ was released in May 2005. Among other features, it offers multiple network building algorithms and filters; maps with established metabolic and signaling pathways; advanced network comparison option; statistical cross-referencing and scoring between networks, pathways and functional processes; custom pathway editor.

"We welcome NCI as a new customer", said Julie Bryant VP of Business Development. "Cancer datasets are inherently complex for interpretation because multiple pathways and cell types are affected. Therefore, the requirements for data mining techniques and tools in oncology are high. We are very pleased that NCI scientists chose MetaCore™ as an enterprise, institution-wide system".

Download this press release in PDF format.

GENEGO IS AWARDED NIEHS GRANT IN TOXICOGENOMICS

St. Joseph, Michigan, May 24th, 2005 - GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today they have received a Phase I SBIR grant from the National Institute of Environmental Health Sciences for the elucidation and analysis of signaling and metabolic networks implicated in cellular response to drugs and toxins. In the first phase of research, publicly available data will be re-analyzed by GeneGo scientists using the company's flagship systems biology platform, MetaCore™.

"Over the past few years, we have witnessed an unprecedented accumulation of gene expression and other high throughput data in toxicity research", said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. "This has been mainly rat and mouse microarray data that has been interrogated with then currently available tools, but some important biological mechanisms and patterns were missed, as they can be only accessed via analysis of biological networks. Now we intend to re-examine the data from different microarray platforms and identify specific modules, "signature networks", characteristic for toxic effects and conserved cross-platform".

"MetaCore gene network analysis will address a critical need in drug safety evaluation by the identification of novel diagnostic biomarkers for adverse responses to drugs or chemicals", said Professor Craig Giroux from Wayne State University, a consultant on the grant. "In addition, these unique Gene Network Signature motifs will provide a valuable resource in support of biomarker development programs for comparative toxicogenomics and predictive risk assessment of environmentally responsive disease in my and other labs."

Download this press release in PDF format.

TGEN LICENSES METACORE™ FROM GENEGO

St. Joseph, Michigan, May 16th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the Translational Genomics Research Institute (TGen) has licensed MetaCore™, GeneGo's platform for mining of high-throughput experimental data in the context of human and mammalian "interactome" and common diseases. MetaCore™ is designed to process "genome scale" data files including microarrays and SAGE gene expression, proteomics and metabolomics. MetaCore™ applies multiple algorithms for generation, comparison and functional interpretation of biological networks and pathways.

"We evaluated MetaCore™ and decided that it was a good fit for TGen," said Dr. Edward Suh, TGen's Chief Information Officer. "GeneGo enables our scientists to generate global pathways and smaller targeted networks, and in addition, extending pathways and networks with GeneGo was a very attractive feature for gaining information."

"We are very pleased to be working with TGen in aiding their mission to make and translate genomic discoveries into advances in human health that will that have a direct impact on patients", said Julie Bryant, VP of business development at GeneGo. "TGen has amassed an impressive group of experts in pre-clinical research and clinical trials that we plan to collaborate with."

About TGen

The Translational Genomics Research Institute (TGen) is a not-for-profit organization whose primary mission is to make and translate genomic discoveries into advances in human health. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project to apply to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.

Download this press release in PDF format.

GENEGO LICENSES METACORE™ TO EXELIXIS

St. Joseph, Michigan, May 13th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Exelixis has licensed MetaCore™, GeneGo's platform for mining of high-throughput experimental data in the context of biological networks, pathways and human diseases. Among other features, MetaCore™ has built manually curated proprietary database of transcriptional factors and receptors supported by unique network algorithms enabling reconstruction of full length regulatory pathways. This allows users to investigate all the genes that regulate a specific gene or a group of genes at the transcription level or build transcriptional regulation networks characteristic for particular diseases and other conditions.

"Exelixis is renowned for its powerful, fully integrated discovery platform that is capable of high-throughput target identification and validation. This has been applied to develop high-quality, differentiated pharmaceutical compounds for the potential treatment of cancer and metabolic diseases in collaborations with top pharmaceutical companies", said Julie Bryant, VP of business development at GeneGo. "We are very pleased that Exelixis chose MetaCore™ to assist their discovery endeavors."

Download this press release in PDF format.

PROCTER & GAMBLE LICENSES METACORE™ AND METABASE™ FROM GENEGO

St. Joseph, Michigan, May 9th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Procter & Gamble Pharmaceuticals, Inc., a subsidiary of The Procter & Gamble Company (NYSE - PG), has licensed MetaCore™ and MetaBase™ from GeneGo. MetaCore™ is a manually curated, proprietary human database with the ability to work with rat, mouse, fly, yeast and worm orthologs. MetaCore™ also includes a suite of software tools for analysis in the context of pathways. MetaBase™ provides researchers with direct access to MetaCore™ content and the ability to add their own algorithms and data to the MetaCore™ schema.

GeneGo's MetaCore™ platform has unique interoperability by allowing users to examine multiple types of data concurrently such as gene expression, proteomics and metabolomics in the context of biological networks and pathways. MetaCore™ also allows users to edit pathways, add their own knowledge and annotations. MetaBase™ is an open-architecture, manually curated content database with information on mammalian signaling, metabolism, transcription factors, receptors, drug targets and bioactive chemistry.

"We are glad to see Procter & Gamble choosing our products to support their R&D efforts", said Julie Bryant, VP Business development of GeneGo. "We are pleased that a company of the caliber of P&G recognizes the potential value that our manually curated databases and analytical tools can add to their already strong R&D programs."

Download this press release in PDF format.

GENEGO RELEASES METACORE™ VERSION 2.5

St. Joseph, Michigan, May 2nd, 2005 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today the release of a major new version of its flagship data mining suite MetaCore™ 2.5. The new version features fine mapping of human metabolism, transcription regulation and signaling; novel network building algorithms, filters and statistical procedures for multi-variant interpretation of human networks in terms of canonical pathways and functional processes. Primarily a human system, these tools are also applied for analysis of rat, mouse, fly, worm and yeast data.

"Over the past five years of development, we have undertaken for MetaCore™, we have always focused on the quality of the manually curated content and its utility for laboratory research; and these principles are emphasized in the new version," said Dr. Tatiana Nikolskaya, Chief Scientific Officer, President and Founder of GeneGo. "First, we have completed the first fine mapping of human metabolism at the "sub-EC number" level of individual proteins (isozymes) and substrates. Second, we have resolved and networked virtually all human transcription factors and known receptors. Third, we have added novel network building algorithms and refined the existing ones. We have also developed a comprehensive toolkit for the statistical analysis of networks generated on the fly; including the evaluation and scoring of the relevance of networks to the experimental data, subcellular localization, canonical pathways and GO functional processes. Finally, we have added a large curated database of drugs, drug targets and diseases."

"Over the last two years, MetaCore™ has become the platform of choice for functional analysis of genome scale experimental datasets in human and model organisms," said Julie Bryant, GeneGo's VP of business development. "In version 2.5, we have substantially expanded its content and capabilities in interpretation of mammalian "interactome". The current version is a mature third generation tool, whose features reflect numerous suggestions by our customers and collaborators in academy and industry. We also continue to maintain flexibility by integrating MetaCore™ with in house and third party algorithms as well as providing flexible business models for licensing."

Download this press release in PDF format.

ORGANON LICENSES METACORE™ FROM GENEGO

St. Joseph, Michigan, April 19th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that N.V. Organon has licensed MetaCore™, GeneGo's platform for mining of high-throughput experimental data in the context of biological networks and human diseases. MetaCore™ is an enterprise platform being installed in the majority of the top Pharmaceutical companies internationally. The suite includes a comprehensive, manually curated database which covers all levels of human cellular functionality, as well as rat, mouse, fly, worm and yeast orthologs, and functional information on over 3,000 human diseases and thousands of drugs connected with pathway targets Organon plans to use MetaCore™ in pre-clinical research across various therapeutic areas and departments.

"We evaluated several platforms and decided that MetaCore™ was the best fit for our current needs at Organon. We are very much looking forward to working closely with GeneGo," said Dr. Peter Groenen, senior research scientist at Organon.

"We are happy that Organon decided to choose MetaCore™ as their systems biology solution", said Julie Bryant, VP of business development at GeneGo. "In addition to extensive content and data mining tools, we emphasize flexible open architecture compatible with different informatics environments and third-party software. We are glad that this strategy is appreciated by researchers in different areas of drug discovery. Organon is one of the leading companies focused on hormone therapy, fertility and mental health and we look forward to working closely with them on making advances in these areas using systems biology tools."

About Organon

Organon - with shared head offices in Roseland, NJ, USA and Oss, The Netherlands - creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.

Download this press release in PDF format.

GENEGO INC. IS AWARDED NCI GRANT FOR ANALYSIS OF CANCER NETWORKS

St. Joseph, Michigan, February 7th, 2005 - GeneGo Inc., a leading provider of databases and software for systems biology, announced today that they will be receiving a Phase I SBIR grant from the National Cancer Institute for elucidation and analysis of cellular networks implicated in breast cancer. GeneGo's MetaCore™, an integrated systems biology platform for mining of high-throughput experimental data will be utilized for advanced analysis.

"We are pleased to win this competitive grant from a premier cancer research institution," said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. "It took our team many years to build tools and pathway content that is comprehensive enough for the analysis of complex human diseases. We will now apply these tools to identify network models and additional patterns in public OMICs cancer data that have been missed by other methods."

Download this press release in PDF format.

GLAXOSMITHKLINE LICENSES METABASE™ FROM GENEGO

Company licenses MetaBase™ systems biology database

St. Joseph, Michigan, January 31st, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that GlaxoSmithKline (GSK) has licensed MetaBase™, GeneGo's database of human biology and medicinal chemistry. MetaBase™ represents a comprehensive, manually curated database which covers all levels of human cellular functionality, from GPCRs and other receptors to signal transduction cascades, transcriptional factors, core effector networks, endogenous and xenobiotics metabolism and the relevant bioactive compounds (metabolites and xenobiotics). GSK intends to apply MetaBase™ towards a broad range of applications in pre-clinical drug discovery, and to integrate MetaBase™ content with their internal informatics systems.

"We are happy that GSK decided to in-license MetaBase™ based on its comprehensive coverage and its flexible architecture that will allow them to integrate MetaBase™ in to their current environment" said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "GSK is known for its strong research record in the areas of molecular modeling and systems biology, and we are pleased that their experts find MetaBase™ useful for the internal programs."

Download this press release in PDF format.

RNAI CO., LTD. (RCL) LICENSES METACORE™ FROM GENEGO AND COLLABORATES IN PLATFORM DEVELOPMENT

St. Joseph, Michigan, January 24th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that RCL has licensed MetaCore™ for its RNA interference drug discovery efforts. MetaCore™ is an integrated platform for the analysis of different types of experimental data in drug discovery. MetaCore™ applies a proprietary, manually curated, human protein interaction and pathway database to drug discovery. The flexible database architecture enables straightforward integration of in house and third party software and databases. MetaCore™ also has easy to use software for building, visualization and analysis of tissue specific biological networks with and without experimental data.

"We looked at several systems biology packages and found that MetaCore™ suited our needs the best." said Mr.Yukikazu Natori, Chairman of RNAi. "The system is flexible for customization, and the GeneGo team is open minded for collaborative development. We needed a flexible partner that was willing to integrate with our current siRNA technology." "We welcome RCL as our first Japanese customer." said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "RCL has built an impressive and unique technology portfolio in the RNA interference area. Their findings are very synergistic with pathway analysis of complex diseases we are working on. We consider this agreement as the first step in long term collaboration in the intersection of these two exciting technologies."

About RNAi

RCL (www.rnai.co.jp) is a biotechnology company in the field of functional genomics based on RNA interference. RCL conducts two types of business. One is research support business for life science and the other is drug discovery business. RCL's unparallel RNA interference science and technology achieves high specificity of gene knock-down while minimizing unwanted off-target effects. RCL has already identified and applied the patent about 820,000 kinds of siRNA/shRNA/Oligo interference for all of human and mice genes known publicly. RCL's licensees can access to the most comprehensive RNAi design system, siDirect™ with usage of 820,000 sequences and get high-quality chemically synthetic siRNA manufactured by Proligo, siPerfect™ at the most attractive price in the market. RCL currently has two business offices and a wet lab and a dry lab in Japan with 20 employees and plans to enhance GMP functionality for preclinical study this year.

Download this press release in PDF format.

ALTANA PHARMA AG LICENSES METACORE™ FROM GENEGO

St. Joseph, Michigan, January 21th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Altana Pharma AG has licensed MetaCore™. MetaCore™ is a comprehensive platform that contains proprietary, manually curated, human data that is curated by GeneGo's staff of PhD's following strict quality control guidelines. The database architecture is flexible, which allows changes to be made quickly and makes integration straight forward. This was a key component to Altana when choosing a systems biology platform. MetaCore™ also has a software component that allows for concurrent visualization of multiple types of data. GeneGo has led the way in systems biology to allow more than just microarray data to be visualized in the context of pathways.

"We will use MetaCore™ for biological interpretation of genomics data and hypothesis generation" said Timo Wittenberger, Ph.D., leader of the bioinformatics group at ALTANA Pharma. "Our aim is a more profound understanding of patho-mechanisms which will allow us to develop more innovative drugs. MetaCore™ helps us here by representing our data in the context of public knowledge."

"We are pleased to have more international companies using MetaCore™ based on its comprehensive coverage and its flexible architecture that will allow them to integrate MetaCore™ in to their current environment" said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "Altana is known for its research in the areas of gastrointestinal and respiratory indications and we are pleased that they are using MetaCore™ to provide more insight to their drug discovery effort in these areas."

About ALTANA Pharma

ALTANA Pharma AG is the pharmaceutical division of ALTANA AG, headquartered in Konstanz, Germany. The international pharmaceutical group employs more than 8,200 people in 30 subsidiaries and is present in markets in Europe, North and South America, Asia, South Africa and Australia. In 2003, the company achieved sales of about €2 billion, up 6% from 2002. ALTANA Pharma concentrates on innovative pharmaceutical products in therapeutics, imaging (contrast media) and OTC medication. Therapeutics, the most important business area, is based on prescription drugs for gastrointestinal and respiratory diseases. Research focuses on gastroenterology, respiratory/inflammation and oncology.

Download this press release in PDF format.

GENEGO LAUNCHES METADRUG™ FOR SYSTEMS - ADME/TOX

St. Joseph, MI. - January 14th, 2005, GeneGo, Inc., A leading systems biology company, today announced the official launch of MetaDrug™ V1.0. MetaDrug™ is a pioneering Systems-ADME/TOX platform which combines software for predicting metabolites and over 40 ADME/Tox properties with visualization and analysis of toxicogenomics and metabolomics data. MetaDrug™ can be used as a stand alone product or together with MetaCore™, GeneGo's flagship analytical platform.

"MetaDrug™ is the first commercial product that merges ADME/TOX predictions in human with systems biology", said Dr. Sean Ekins, Vice President, Computational Biology. MetaDrug™ contains an extensive, expert curated database of small molecule content related to human drug metabolism, algorithms for predicting and prioritization of metabolites, the ability to highlight reactive metabolites and the most extensive set of predictive ADME/TOX models available. MetaDrug™ also enables analysis of toxicogeneomics data that can be visualized on networks and on static pathways maps. The user can therefore interpret both chemical and biological data in the context of the whole organism, merging predictions with empirical data when available. MetaDrug™ will be useful for preclinical assessment of molecules and their predicted properties. MetaDrug™ is also complimentary with MetaCore™ enabling researchers to build and analyze protein-protein, protein-ligand and genetic interaction networks using GeneGo's comprehensive databases of human biology and active chemistry. Ultimately both products enable the prediction of interactions of a small molecule with both xenobiotic and endogenous metabolism, regulation and cellular signaling.

Download this press release in PDF format.

TNO LICENSES GENEGO'S METACORE™

St Joseph, MI and Zeist, Netherlands - January 3rd 2005, GeneGo Inc., a leading systems biology company, announced today that TNO of the Netherlands has licensed its analytical tool MetaCore™. The product will be used internally by TNO's nutritional division, as well as in collaboration with the NuGO consortium of 21 universities throughout Europe (www.nugo.org). MetaCore™ is an integrated systems biology platform which includes a proprietary, manually curated database of eukaryotic biology and bioactive chemistry, network analysis software and a toolkit for visualization and management of high-throughput experimental data.

"We chose MetaCore™ as it has the most comprehensive, detailed database of human metabolism and signaling, and is also a one-stop shop for our systems analysis needs" said Dr Ben van Ommen, Senior Research Fellow in Nutritional Systems Biology of TNO. "Experimental data in nutrition are inherently complex, as the diet-influenced changes in disease onset and progression are subtle and multi-factorial. We also have the data from both human and model animals. In MetaCore™, we can upload and compare all these data on the same networks and pathways and then analyze the networks with a variety of tools."

"We are very happy with TNO's decision to apply MetaCore™ in nutrigenomics studies", said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. "Although MetaCore™ is broadly used for drug discovery in industry and academy, this is its first non-pharmaceutical application. We consider the collaboration with TNO as an important step forward in adaptation of systems biology technology for everyday use."

About TNO

TNO is one of the leading research and technology organizations in Europe. It was established by the Dutch Government in 1932. TNO has a workforce of 5,500 employees, working in areas such as life sciences, industrial research, infrastructure, ICT and defense and safety. Within the life sciences area, focus is on nutrition and toxicology (including systems biology), analysis, working environment, microbiology and product innovation. The main markets for life sciences contract research are the food, chemical and pharmaceutical industries.

Download this press release in PDF format.

ARIADNE GENOMICS AND GENEGO COLLABORATE IN DELIVERING ADVANCED SYSTEMS BIOLOGY TOOLS

Rockville, MD and St. Joseph, MI. September 20, 2004 - Ariadne Genomics Inc. and GeneGo, Inc., two leading systems biology companies, today announced integration and co-marketing of tools for functional analysis of high-throughput experimental data. Ariadne Genomics" MedScan TextMiner automated text processing pipeline will be integrated and co-marketed with MetaCore™, GeneGo"s flagship analytical platform that includes proprietary, manually curated databases of human biology and chemistry.

"We are pleased to join forces with Ariadne Genomics, the market leader in automated text mining of biomedical information", said Dr. Tatiana Nikolskaya, President and CSO of GeneGo. "MetaCore™ is known for its extensive, expert curated content and analytical tools. Now, we are adding to the platform the most advanced Natural Language Processing (NLP) engine available today. With the integration of MedScan TextMiner, our customers will have more options and flexibility in extracting relevant information from experimental data".

"We are happy to collaborate with GeneGo", said Dr. Ilya Mazo, President of Ariadne Genomics. "Our goal is to deliver comprehensive tools for genomic data analysis to the working desk of every scientist, and this collaboration provides researchers with unprecedented power and flexibility in text and data mining. Specifically, they can build and analyze protein-protein, protein-ligand and genetic interaction networks using GeneGo"s high quality databases of human biology and active chemistry. At the same time, they will be able to see the bigger picture with the vast space of protein interactions and regulations extracted from MEDLINE publications, proprietary and public domain databases".

MetaCore™ features maps, pathways and networks for almost all known human proteins; parsers for importing data from all major microarray platforms, SAGE, proteomics and metabolomics data; seven proprietary network building algorithms; flexible visualization and data exchange tools.

MedScan TextMiner utilizes a proprietary Natural Language Processing engine to automatically process MEDLINE abstracts, articles, and other scientific text in TXT, PDF, HTML and other formats. It extracts functional associations among proteins, cell processes, small molecules etc., and recognizes types of regulatory mechanisms involved, and the effects of regulation.

About Ariadne Genomics

Ariadne Genomics develops software tools for systems biology, based on its innovative Natural Language Processing (NLP) and statistical algorithms: PathwayAssist, an intuitive desktop software tool for reconstruction, analysis and visualization of cell regulatory pathways; MedScan TextMiner, an automated scientific text processing tool, extracting information from MEDLINE abstracts, articles and other text resources; ResNet, a comprehensive molecular networks database, created by automated extraction of biological facts from the entire PubMed, and Seqware, a PC-based BLAST server, storing and managing the entire

Download this press release in PDF format.

GENEGO ADDS BRISTOL-MYERS SQUIBB TO CUSTOMER BASE

Company licenses MetaCore™ systems biology database

St. Joseph, Michigan, August 10, 2004 - GeneGo, Inc., a leading systems biology company, today announced that Bristol-Myers Squibb has licensed its MetaCore™ data mining suite that combines analytical tools, data content and algorithms for understanding complex interconnected pathways that are affected in common human diseases.

MetaCore™'s manually curated content covers all levels of cellular functionality from GPCRs and other receptors to signal transduction cascades, transcriptional factors, core effector networks, endogenous and xenobiotics metabolism and the relevant chemical compounds (metabolites and xenobiotics). The main application of MetaCore™ is in visualization and analysis of complex experimental data including microarray gene expression, SAGE and SNP DNA sequences, proteomics and metabolites profiles.

"BMS is the fifth major life science company which licensed MetaCore™ for internal development in recent months" said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "We are pleased that MetaCore™'s features, in particular its curated content and ability to integrate customer-generated data into the database, meet Bristol-Myers Squibb's expectations in systems biology."

Download this press release in PDF format.

GENEGO RELEASES VERSION 2.0 OF METACORE™

Improvements to data parsing systems and user interface increase usability

St. Joseph, Michigan, August 9, 2004 - GeneGo, Inc., a leading systems biology company, today released its integrated data mining suite MetaCore™ version 2.0 to the general public. The new version of MetaCore™ features over 300 functional maps of human biology, additional parsers for importing data directly from Affymetrix and Agilent microarrays, analyzed data from Silicon Genetic's GeneSpring and Rosetta's Resolver, SAGE, proteomics and metabolomics data. MetaCore™ also has seven new network building algorithms, and additional visualization tools which enhance the flexibility and efficiency of analysis.

MetaCore™ is based on a comprehensive, interactive database of human biology. MetaCore™'s manually curated content covers all levels of cellular functionality from GPCRs and other receptors to signal transduction cascades, transcriptional factors, core effector networks, endogenous and xenobiotics metabolism and the relevant chemical compounds (metabolites, drugs and ligands). The main application of MetaCore™ is in visualization and analysis of complex experimental data including microarray gene expression, SAGE and SNP DNA sequences, proteomics and metabolites profiles.

"One of MetaCore™'s key advantages is its integration of many different data types, which enables a multileveled approach to understanding cellular functionality. The completeness of MetaCore™'s content, high confidence in our pathways and interactions and easy-to-use intuitive interface make MetaCore™ 2.0 a valuable resource for life scientists involved in "high-throughput" experimental research," said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "Systems biology is a very new area with few guidelines. We listen to our academic and industrial customers and collaborators and develop MetaCore™ to address their needs and wishes. Our proprietary architecture allows us to make changes and enhancements very quickly."

Download this press release in PDF format.

GENEGO ENTERS LICENSING AGREEMENT WITH INVITROGEN CORPORATION

St. Joseph, Michigan, June 1, 2004 - GeneGo, Inc., a company with a proprietary computational platform for Systems Biology that combines analytical tools, data content and algorithms for understanding complex interconnected pathways that are affected in common human diseases, today announced that it has entered into a multi-year licensing agreement with Invitrogen Corp. (Nasdaq: IVGN), a provider of essential life science technologies for disease research and drug discovery. Under the agreement, the companies plan to work closely together to develop new capabilities. Further details and financial arrangements were not disclosed at this time, but will be divulged in greater detail as milestones of the collaboration are achieved.

"We are delighted to work with Invitrogen towards our shared goal of providing life science researchers with the tools they need to produce meaningful answers from their experiments," said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo.

"We are impressed with the quality and usability of biological pathways from GeneGo. Licensing of these pathways will help us in making bioinformatics an intrinsic part of Invitrogen's solutions set for life science research," said Michael Stapleton, Ph.D., General Manager and Vice President of Invitrogen's bioinformatics business.

Download this press release in PDF format.

SEAN EKINS, PH.D. JOINS GENEGO AS VICE PRESIDENT OF COMPUTATIONAL BIOLOGY

St. Joseph, Michigan, February 23, 2004 - GeneGo today announced that Sean Ekins, Ph.D. joined the Company as the Vice President for Computational Biology. Dr. Ekins is a world renowned scientist in the area of in vitro and computational ADME and toxicity, an important area of pharmaceutical drug discovery and development. Prior to GeneGo, Dr. Ekins held various research positions at Eli Lilly, Pfizer and was most recently Associate Director, Computational Drug Discovery at Concurrent Pharmaceuticals. He has authored over 50 peer reviewed articles, book chapters, reviews as well as several patents relating to computational and screening technologies. Dr. Ekins is also on the editorial boards of several journals. Dr. Ekins earned his Ph.D. from The University of Aberdeen.

"We are happy to welcome Dr. Ekins to our team. In addition to his outstanding research record, he brings invaluable hands-on expertise at leading drug companies" said Dr. Tatiana Nikolskaya, President & CSO of GeneGo. "Sean will lead our program in ADME/Tox, namely development of MetaDrug™, a systems biology platform for early prediction of metabolic fate and human toxicity of novel drug molecules".

"I am very excited to join GeneGo" said Dr.Ekins, "I was attracted by GeneGo's unique approach to Systems Recontruction technology which links human metabolism with regulation and chemistry. We will leverage this valuable technology in a very novel product in the ADME/Tox area. MetaDrug™ will be capable of analysis of multiple types of pre-clinical data for making reliable compound selection decisions in early lead discovery".

Download this press release in PDF format.

GENEGO NAMES CHARLES R. CANTOR, PH.D., TO SCIENTIFIC ADVISORY BOARD

St. Joseph, Michigan, December 15, 2003 - GeneGo today announced the appointment of Charles R.Cantor, Ph.D. to its Scientific Advisory Board. A world-renowned scientist, Dr. Cantor has authored over 360 peer reviewed articles, the first textbook on genomics Genomics: The Science and Technology of the Human Genome Project, co-authored a three volume textbook on Biophysical Chemistry, and been granted 54 patents.

"I'm pleased to serve on GeneGo's scientific advisory board," said Dr. Cantor. "GeneGo's computational platform technology will enable researchers to integrate information from several sources and efficiently analyze it for a clearer understanding of disease mechanics."

"We are delighted to welcome Dr. Cantor to our Scientific Advisory Board," said Dr. Tatiana Nikolskaya, President of GeneGo. "His scientific expertise and industry name recognition will be a valuable addition as we develop new products and move into additional markets".

Dr. Cantor is currently Chief Scientific Officer and a Board Director of SEQUENOM, Inc. He is also director of the Center for Advanced Biotechnology at Boston University. Dr. Cantor has held positions at Columbia University and University of California at Berkeley, and was director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. In 2002, he founded SelectX Pharmaceuticals.

Download this press release in PDF format.

THE SAN DIEGO SUPERCOMPUTING CENTER LICENSES GENEGO'S METACORE™ PLATFORM FOR SYSTEMS BIOLOGY APPLICATIONS

New Buffalo, Michigan, July 23, 2003 - GeneGo announced today that it will license its MetaCore™ platform to the San Diego Supercomputing Center (SDSC). MetaCore™ is a proprietary computational platform for Systems Biology that combines analytical tools, data content, and algorithms for understanding the complex interconnected pathways that are affected in common human diseases. Under the agreement, the SDSC will make MetaCore™ available to SDSC and the University of California San Diego (UCSD) researchers to apply to their own research programs. GeneGo will provide training and host educational seminars, symposia, and user group meetings. Additional details about the agreement were not disclosed.

"We are pleased that one of the world's most prestigious centers for computational biosciences is licensing the MetaCore™ Platform," said Dr. Tatiana Nikolskaya, CEO of GeneGo. "SDSC has consistently been at the forefront of applying leading-edge information systems to biomedical research, and their decision to license MetaCore™ is an important validation of the power and utility of the Systems Biology solution we have developed."

Several SDSC faculty members already have plans to work with MetaCore™ in their research programs. One faculty member, Dr. Phil Bourne, Professor of Pharmacology, will use MetaCore™ as part of his Encyclopedia of Life project. This in silico high-throughput proteomics project is an open collaboration that aims to develop a flexible, powerful reference system to catalog, calculate three-dimensional models, and assign biological functions for the complete proteome of every living species. Another faculty member, Dr. Shankar Subramanian, Professor of Bioengineering, will use MetaCore™ as part of his efforts in the Alliance for Cellular Signaling (AfCS) collaboration. AfCS is a large-scale collaboration designed to answer global questions about cell signaling networks to facilitate quantitative modeling and eventually lead to a full understanding of how cells interpret signals in a context-dependent manner.

"The interactions between GeneGo and SDSC have been quite fruitful in the last few months," said Professor Kim Baldridge, Director of Integrative Computational Sciences at the SDSC. "We look forward to providing MetaCore™ to the research community we serve, and to building a strong, collaborative relationship with GeneGo."

About the San Diego Supercomputing Center

The San Diego Supercomputing Center (SDSC) is a national laboratory whose mission is to develop and apply high-performance information technologies for science and society. SDSC is a research unit of the University of California, San Diego, and the leading-edge site of the National Partnership for Advanced Computational Infrastructure (NPACI), a 48-institution partnership funded by the National Science Foundation (NSF)to create computational environments for tomorrow's scientific discovery. SDSC is a recognized world leader in computational biosciences, hosting the primary Protein Data Bank web and data servers, and playing the key bioinformatics and information coordination roles for the Biomedical Informatics Research Network, the Alliance for Cell Signaling, the Joint Center for Structural Genomics, the National Biomedical Computation Resource, and the Computational Center for Macromolecular Structure. Additional information is available at www.sdsc.edu.

Download this press release in PDF format.

GENEGO RECEIVES 1.4 MILLION DOLLAR AWARD FROM THE MICHIGAN LIFE SCIENCE CORRIDOR

New Buffalo, Michigan, June 16, 2003 - GeneGo announced today the receipt of a 1.4 million dollar award from the Michigan Life Science Corridor (MLSC). With over 151 companies competing for 18 awards, it reinforces the life science industry's endorsement of GeneGo's technology.

"We are delighted to have received this award from MLSC," said Dr. Tatiana Nikolskaya, CEO of GeneGo. "Our MetaCore™ platform, which contains the largest human content available today, has established us as a leader in computational systems biology. MetaCore™ is the first commercially available computational platform for human Systems Biology, and is designed to assist pharmaceutical researchers in the areas of target selection, prioritization, and validation, as well as biomarker identification. We will use the funds to further develop this product and to expand our sales, customer support, and application divisions."

GeneGo will maintain its position as one of the leaders in the field by continuing to focus on new product development. Plans for the MetaCore™ platform include more advanced visualization tools, additions to the disease map library, and staying current with all relevant published literature. The company is also committed to increasing the field scientist team so that they can provide support to customers on how to apply MetaCore™ to their research programs.

In addition to the MLSC award, GeneGo has received a Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences, a division of the NIH. This grant will be used to support the development of its next product, MetaDrug™, an in silico platform for predicting metabolism and possible toxic effects of novel drug candidates. Expected to launch in the latter part of this year, MetaDrug™ will integrate advanced QSAR and expert system approaches with GeneGo's extensive database on human pathways and their software for reconstruction and visualization of metabolic and cell signaling networks. The company's growing recognition and unique technology portfolio will pave the way for additional awards from state and federal programs.

MetaCore™ is a trademark of GeneGo, Inc.

Download this press release in PDF format.

GENEGO RELEASES THE METACORE™ PLATFORM, A NEW SYSTEMS BIOLOGY SOLUTION FOR DRUG RESEARCH AND DEVELOPMENT APPLICATIONS

New Buffalo, Michigan, March 25, 2003 - GeneGo announced today the commercial launch of MetaCore™, a proprietary computational platform for Systems Biology that combines analytical tools, data content, and algorithms for understanding the complex interconnected pathways that are affected in common human diseases.

MetaCore™ is the first commercially available computational platform for human Systems Biology and has been designed to assist pharmaceutical researchers in the areas of target selection, prioritization, and validation, as well as biomarker identification. MetaCore™ integrates all levels of cellular functionality - from membrane receptors to signal transduction, transcription factors, and effector networks - using in silico models to explore and predict how different disease states, and different levels of metabolites and xenobiotics, can affect the performance of the system.

A unique feature of the MetaCore™ Platform is its ability to allow the researcher to integrate and visualize data from many different biological levels and types of experiments within the same system, and in the context of the existing knowledge in the literature and the extensive systems biology databases provided with the platform. MetaCore™ allows exploration of the relationships between what is happening at the level of the genome (such as genetic variation), transcriptome, proteome (including post-translational modifications and protein interactions), and metabolome.

"Pharmaceutical researchers are required to make important decisions regarding target prioritization and validation which directly affect the value of their companies' portfolio of products in development," said Dr. Tatiana Nikolskaya, CEO of GeneGo. "These decisions need to be made in the context of all of the different types the data at hand, and in the past, this has been extremely difficult," continued Nikolskaya. "The data analysis tools available until now only allowed the researcher to look at one level of biological data at a time, such as RNA expression information. Clearly there are many downstream events, and complex interactions and reactions in biological systems, that must be considered as well. The 'enterprise-wide' data storage systems have not provided the answer either," she added, "as they organize data by workflow or project, and fail to provide a framework or ontogeny for how all the data is interrelated that is consistent with the fundamental mechanisms of biology. This is where MetaCore™'s strength lies."

The MetaCore™ Platform's software provides data mining capabilities, and allows data from the customer's experiments to be overlaid onto the pathways. The capability to analyze and overlay RNA expression data is provided as a standard feature, and currently supported data formats are the Affymetrix U95Av2, HG-U133A, and HG-U133B GeneChips, Agilent microarrays, and public and proprietary SAGE data. Customers can choose to add optional data parsers for proteomics, metabolomics, or other levels of biological data, which are custom-built to work with the specific type of data being generated.

Download this press release in PDF format.